Nicholas P. Restifo - Publications

Affiliations: 
The George Washington University, Washington, DC, United States 
Area:
Immunology, Oncology, Biochemistry

387 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Palmer DC, Webber BR, Patel Y, Johnson MJ, Kariya CM, Lahr WS, Parkhurst MR, Gartner JJ, Prickett TD, Lowery FJ, Kishton RJ, Gurusamy D, Franco Z, Vodnala SK, Diers MD, ... ... Restifo NP, et al. Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade. Med (New York, N.Y.). PMID 36007524 DOI: 10.1016/j.medj.2022.07.008  0.453
2022 Kishton RJ, Patel SJ, Decker AE, Vodnala SK, Cam M, Yamamoto TN, Patel Y, Sukumar M, Yu Z, Ji M, Henning AN, Gurusamy D, Palmer DC, Stefanescu RA, Girvin AT, ... ... Restifo NP, et al. Cancer genes disfavoring T cell immunity identified via integrated systems approach. Cell Reports. 40: 111153. PMID 35926468 DOI: 10.1016/j.celrep.2022.111153  0.431
2021 Kishton RJ, Vodnala SK, Vizcardo R, Restifo NP. Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activity. Current Opinion in Immunology. 74: 39-45. PMID 34710751 DOI: 10.1016/j.coi.2021.10.001  0.435
2021 Mo F, Yu Z, Li P, Oh J, Spolski R, Zhao L, Glassman CR, Yamamoto TN, Chen Y, Golebiowski FM, Hermans D, Majri-Morrison S, Picton LK, Liao W, Ren M, ... ... Restifo NP, et al. An engineered IL-2 partial agonist promotes CD8 T cell stemness. Nature. PMID 34526724 DOI: 10.1038/s41586-021-03861-0  0.396
2021 Hippen KL, Furlan SN, Roychoudhuri R, Wang E, Zhang Y, Osborn MJ, Merkel SC, Hani S, MacMillan ML, Cichocki F, Miller JS, Wagner JE, Restifo NP, Kean LS, Blazar BR. Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion. Cytotherapy. PMID 33893050 DOI: 10.1016/j.jcyt.2021.02.118  0.378
2021 Xu N, Palmer DC, Robeson AC, Shou P, Bommiasamy H, Laurie SJ, Willis C, Dotti G, Vincent BG, Restifo NP, Serody JS. STING agonist promotes CAR T cell trafficking and persistence in breast cancer. The Journal of Experimental Medicine. 218. PMID 33382402 DOI: 10.1084/jem.20200844  0.466
2020 Dersh D, Phelan JD, Gumina ME, Wang B, Arbuckle JH, Holly J, Kishton RJ, Markowitz TE, Seedhom MO, Fridlyand N, Wright GW, Huang DW, Ceribelli M, Thomas CJ, Lack JB, ... Restifo NP, et al. Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. Immunity. PMID 33271120 DOI: 10.1016/j.immuni.2020.11.002  0.354
2020 Gurusamy D, Henning AN, Yamamoto TN, Yu Z, Zacharakis N, Krishna S, Kishton RJ, Vodnala SK, Eidizadeh A, Jia L, Kariya CM, Black MA, Eil R, Palmer DC, Pan JH, ... ... Restifo NP, et al. Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies. Cancer Cell. 37: 818-833.e9. PMID 32516591 DOI: 10.1016/J.Ccell.2020.05.004  0.516
2020 Pérez-Guijarro E, Yang HH, Araya RE, El Meskini R, Michael HT, Vodnala SK, Marie KL, Smith C, Chin S, Lam KC, Thorkelsson A, Iacovelli AJ, Kulaga A, Fon A, Michalowski AM, ... ... Restifo NP, et al. Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy. Nature Medicine. PMID 32284588 DOI: 10.1038/S41591-020-0818-3  0.412
2020 Dextras C, Dashnyam M, Griner LAM, Sundaresan J, Chim B, Yu Z, Vodnala S, Lee CR, Hu X, Southall N, Marugan JJ, Jadhav A, Restifo NP, Acquavella N, Ferrer M, et al. Identification of Small Molecule Enhancers of Immunotherapy for Melanoma. Scientific Reports. 10: 5688. PMID 32231230 DOI: 10.1038/S41598-020-62369-1  0.461
2020 Malekzadeh P, Yossef R, Cafri G, Paria BC, Lowery FJ, Jafferji M, Good ML, Sachs A, Copeland AR, Kim SP, Kivitz S, Parkhurst MR, Robbins PF, Ray S, Xi L, ... ... Restifo NP, et al. Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31996390 DOI: 10.1158/1078-0432.Ccr-19-1874  0.436
2020 Zhang L, Davies JS, Serna C, Yu Z, Restifo NP, Rosenberg SA, Morgan RA, Hinrichs CS. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models. Journal For Immunotherapy of Cancer. 8. PMID 31959727 DOI: 10.1136/Jitc-2019-000210  0.37
2019 Kumar Vodnala S, Restifo NP. Identifying the source of tumour-infiltrating T cells. Nature. 576: 385-386. PMID 31844254 DOI: 10.1038/D41586-019-03670-6  0.487
2019 Good ML, Vizcardo R, Maeda T, Tamaoki N, Malekzadeh P, Kawamoto H, Restifo NP. Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells. Journal of Visualized Experiments : Jove. PMID 31710026 DOI: 10.3791/59997  0.562
2019 Schwartz AL, Nath PR, Allgauer M, Lessey-Morillon EC, Sipes JM, Ridnour LA, Morillon Ii YM, Yu Z, Restifo NP, Roberts DD. Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation. Cancer Immunology, Immunotherapy : Cii. PMID 31628526 DOI: 10.1007/S00262-019-02397-7  0.517
2019 Yamamoto TN, Kishton RJ, Restifo NP. Developing neoantigen-targeted T cell-based treatments for solid tumors. Nature Medicine. PMID 31591590 DOI: 10.1038/S41591-019-0596-Y  0.548
2019 Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, Rao A, Restifo NP, Schietinger A, Schumacher TN, Schwartzberg PL, Sharpe AH, Speiser DE, et al. Defining 'T cell exhaustion'. Nature Reviews. Immunology. PMID 31570879 DOI: 10.1038/S41577-019-0221-9  0.48
2019 Vizcardo R, Rafiqul Islam SM, Maeda T, Tamaoki N, Good ML, Klemen ND, Bosch-Marce M, Jia L, Kruhlak MJ, Restifo NP. A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants. Journal of Visualized Experiments : Jove. PMID 31449236 DOI: 10.3791/58672  0.516
2019 Collins N, Han SJ, Enamorado M, Link VM, Huang B, Moseman EA, Kishton RJ, Shannon JP, Dixit D, Schwab SR, Hickman HD, Restifo NP, McGavern DB, Schwartzberg PL, Belkaid Y. The Bone Marrow Protects and Optimizes Immunological Memory during Dietary Restriction. Cell. 178: 1088-1101.e15. PMID 31442402 DOI: 10.1016/J.Cell.2019.07.049  0.399
2019 Lee PH, Yamamoto TN, Gurusamy D, Sukumar M, Yu Z, Hu-Li J, Kawabe T, Gangaplara A, Kishton RJ, Henning AN, Vodnala SK, Germain RN, Paul WE, Restifo NP. Host conditioning with IL-1β improves the antitumor function of adoptively transferred T cells. The Journal of Experimental Medicine. PMID 31405895 DOI: 10.1084/Jem.20181218  0.453
2019 Kanellopoulou C, George AB, Masutani E, Cannons JL, Ravell JC, Yamamoto TN, Smelkinson MG, Jiang PD, Matsuda-Lennikov M, Reilley J, Handon R, Lee PH, Miller JR, Restifo NP, Zheng L, et al. Mg regulation of kinase signaling and immune function. The Journal of Experimental Medicine. PMID 31196981 DOI: 10.1084/Jem.20181970  0.38
2019 Hanada KI, Yu Z, Chappell GR, Park AS, Restifo NP. An effective mouse model for adoptive cancer immunotherapy targeting neoantigens. Jci Insight. 4. PMID 31092734 DOI: 10.1172/Jci.Insight.124405  0.535
2019 Vodnala SK, Eil R, Kishton RJ, Sukumar M, Yamamoto TN, Ha NH, Lee PH, Shin M, Patel SJ, Yu Z, Palmer DC, Kruhlak MJ, Liu X, Locasale JW, Huang J, ... ... Restifo NP, et al. T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science (New York, N.Y.). 363. PMID 30923193 DOI: 10.1126/Science.Aau0135  0.554
2019 Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu YC, Lu L, Zheng Z, Xi L, Epstein M, McIntyre LS, Malekzadeh P, Raffeld M, et al. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 30882547 DOI: 10.1097/Cji.0000000000000260  0.421
2019 Gautam S, Fioravanti J, Zhu W, Le Gall JB, Brohawn P, Lacey NE, Hu J, Hocker JD, Hawk NV, Kapoor V, Telford WG, Gurusamy D, Yu Z, Bhandoola A, Xue HH, ... ... Restifo NP, et al. The transcription factor c-Myb regulates CD8 T cell stemness and antitumor immunity. Nature Immunology. 20: 337-349. PMID 30778251 DOI: 10.1038/S41590-018-0311-Z  0.438
2019 Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC, Jia L, Gartner JJ, Hill V, Yu Z, Restifo NP, Sachs A, Tran E, Lo W, Somerville RP, Rosenberg SA, et al. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. The Journal of Clinical Investigation. PMID 30714987 DOI: 10.1172/Jci123791  0.456
2019 Wei J, Kishton RJ, Angel M, Conn CS, Dalla-Venezia N, Marcel V, Vincent A, Catez F, Ferré S, Ayadi L, Marchand V, Dersh D, Gibbs JS, Ivanov IP, Fridlyand N, ... ... Restifo NP, et al. Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance. Molecular Cell. PMID 30712990 DOI: 10.1016/J.Molcel.2018.12.020  0.362
2019 Yamamoto TN, Lee PH, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, Eidizadeh A, Eil R, Fioravanti J, Gattinoni L, Kochenderfer JN, Fry TJ, Aksoy BA, Hammerbacher J, Cruz AC, ... ... Restifo NP, et al. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. The Journal of Clinical Investigation. PMID 30694219 DOI: 10.1172/Jci121491  0.513
2019 Restifo NP. Hierarchy, Tolerance, and Dominance in the Antitumor T-Cell Response. Journal of Immunotherapy : Official Journal of the Society For Biological Therapy. 24: 193-194. PMID 11395633  0.356
2018 Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, Maseda D, Liberti MV, Paz K, Kishton RJ, Johnson ME, de Cubas AA, Wu P, Li G, Zhang Y, ... ... Restifo NP, et al. Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. Cell. PMID 30392958 DOI: 10.1016/J.Cell.2018.10.001  0.465
2018 Shukla V, Rao M, Zhang H, Beers J, Wangsa D, Wangsa D, Buishand FO, Wang Y, Yu Z, Stevenson H, Reardon E, McLoughlin KC, Kaufman A, Payabyab E, Hong JA, ... ... Restifo N, et al. Identification of Novel Targets for Lung Cancer Therapy Using an Induced Pluripotent Stem Cell Model. Annals of the American Thoracic Society. 15: S127-S128. PMID 29676638 DOI: 10.1513/Annalsats.201707-610Mg  0.31
2018 Jin BY, Campbell TE, Draper LM, Stevanović S, Weissbrich B, Yu Z, Restifo NP, Rosenberg SA, Trimble CL, Hinrichs CS. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. Jci Insight. 3. PMID 29669936 DOI: 10.1172/jci.insight.99488  0.407
2018 Guittard G, Dios-Esponera A, Palmer DC, Akpan I, Barr VA, Manna A, Restifo NP, Samelson LE. The Cish SH2 domain is essential for PLC-γ1 regulation in TCR stimulated CD8T cells. Scientific Reports. 8: 5336. PMID 29593227 DOI: 10.1038/S41598-018-23549-2  0.355
2018 Vizcardo R, Klemen ND, Islam SMR, Gurusamy D, Tamaoki N, Yamada D, Koseki H, Kidder BL, Yu Z, Jia L, Henning AN, Good ML, Bosch-Marce M, Maeda T, Liu C, ... ... Restifo NP, et al. Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System. Cell Reports. 22: 3175-3190. PMID 29562175 DOI: 10.1016/J.Celrep.2018.02.087  0.533
2018 Henning AN, Roychoudhuri R, Restifo NP. Epigenetic control of CD8+ T cell differentiation. Nature Reviews. Immunology. PMID 29379213 DOI: 10.1038/Nri.2017.146  0.461
2018 Henning AN, Klebanoff CA, Restifo NP. Silencing stemness in T cell differentiation. Science (New York, N.Y.). 359: 163-164. PMID 29326263 DOI: 10.1126/Science.Aar5541  0.389
2018 Vizcardo R, Klemen ND, Islam R, Gurusamy D, Tamaoki N, Jia L, Yu Z, Hennings AN, Maeda T, Bosch-Marce M, Good ML, Pack S, Stroncek DF, Flomerfelt FA, Kruhlak MJ, ... Restifo NP, et al. Developing the Next Generation of iPSC Cell-Based Immunotherapies Blood. 132: 3707-3707. DOI: 10.1182/Blood-2018-99-118593  0.544
2018 Restifo NP. Abstract IA25: Identification of essential genes for cancer immunotherapy Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-Ia25  0.543
2017 Klebanoff CA, Crompton JG, Leonardi AJ, Yamamoto TN, Chandran SS, Eil RL, Sukumar M, Vodnala SK, Hu J, Ji Y, Clever D, Black MA, Gurusamy D, Kruhlak MJ, Jin P, ... ... Restifo NP, et al. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. Jci Insight. 2. PMID 29212954 DOI: 10.1172/Jci.Insight.95103  0.472
2017 Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta GU, Chichura A, Shalem O, Tran E, ... ... Restifo NP, et al. Identification of essential genes for cancer immunotherapy. Nature. PMID 28783722 DOI: 10.1038/Nature23477  0.454
2017 Kishton RJ, Sukumar M, Restifo NP. Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metabolism. 26: 94-109. PMID 28683298 DOI: 10.1016/J.Cmet.2017.06.016  0.526
2017 Gurusamy D, Clever D, Eil R, Restifo NP. Novel "Elements" of Immune Suppression within the Tumor Microenvironment. Cancer Immunology Research. 5: 426-433. PMID 28576921 DOI: 10.1158/2326-6066.Cir-17-0117  0.49
2017 Afzali B, Grönholm J, Vandrovcova J, O'Brien C, Sun HW, Vanderleyden I, Davis FP, Khoder A, Zhang Y, Hegazy AN, Villarino AV, Palmer IW, Kaufman J, Watts NR, Kazemian M, ... ... Restifo NP, et al. BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency. Nature Immunology. PMID 28530713 DOI: 10.1038/Ni.3753  0.319
2017 Sukumar M, Kishton RJ, Restifo NP. Metabolic reprograming of anti-tumor immunity. Current Opinion in Immunology. 46: 14-22. PMID 28412583 DOI: 10.1016/J.Coi.2017.03.011  0.513
2017 Hirsh V, Pignata S, Bersanelli M, Gnetti L, Azzoni C, Bottarelli L, Gasparro D, Leonardi F, Silini EM, Buti S, Wennerberg E, Mediero A, Cronstein B, Formenti S, Demaria S, ... ... Restifo NP, et al. Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts Journal of Translational Medicine. 15. DOI: 10.1186/S12967-016-1095-2  0.562
2017 Clever D, Restifo N. Abstract 4932: Oxygen sensing by T cells establishes an immunologically favorable metastatic niche Cancer Research. 77: 4932-4932. DOI: 10.1158/1538-7445.Am2017-4932  0.539
2016 Cruz AC, Ramaswamy M, Ouyang C, Klebanoff CA, Sengupta P, Yamamoto TN, Meylan F, Thomas SK, Richoz N, Eil R, Price S, Casellas R, Rao VK, Lippincott-Schwartz J, Restifo NP, et al. Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction. Nature Communications. 7: 13895. PMID 28008916 DOI: 10.1038/Ncomms13895  0.416
2016 Slaney CY, von Scheidt B, Davenport AJ, Beavis P, Westwood JA, Mardiana S, Tscharke D, Ellis S, Prince HM, Trapani JA, Johnstone RW, Smyth MJ, Teng MW, Ali A, Yu Z, ... ... Restifo NP, et al. Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27965307 DOI: 10.1158/1078-0432.Ccr-16-1860  0.541
2016 Kishton RJ, Sukumar M, Restifo NP. Arginine Arms T Cells to Thrive and Survive. Cell Metabolism. 24: 647-648. PMID 27829132 DOI: 10.1016/J.Cmet.2016.10.019  0.436
2016 Wang QJ, Yu Z, Hanada KI, Patel K, Kleiner D, Restifo NP, Yang J. Pre-clinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27803044 DOI: 10.1158/1078-0432.Ccr-16-1421  0.393
2016 Crompton JG, Sukumar M, Restifo NP. Targeting Akt in cell transfer immunotherapy for cancer. Oncoimmunology. 5: e1014776. PMID 27757294 DOI: 10.1080/2162402X.2015.1014776  0.426
2016 Klebanoff CA, Restifo NP. Customizing Functionality and Payload Delivery for Receptor-Engineered T Cells. Cell. 167: 304-306. PMID 27716501 DOI: 10.1016/J.Cell.2016.09.033  0.397
2016 Eil R, Vodnala SK, Clever D, Klebanoff CA, Sukumar M, Pan JH, Palmer DC, Gros A, Yamamoto TN, Patel SJ, Guittard GC, Yu Z, Carbonaro V, Okkenhaug K, Schrump DS, ... ... Restifo NP, et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature. PMID 27626381 DOI: 10.1038/Nature19364  0.447
2016 Clever D, Roychoudhuri R, Constantinides MG, Askenase MH, Sukumar M, Klebanoff CA, Eil RL, Hickman HD, Yu Z, Pan JH, Palmer DC, Phan AT, Goulding J, Gattinoni L, Goldrath AW, ... ... Restifo NP, et al. Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche. Cell. 166: 1117-1131.e14. PMID 27565342 DOI: 10.1016/J.Cell.2016.07.032  0.535
2016 Moogk D, Zhong S, Yu Z, Liadi I, Rittase W, Fang V, Dougherty J, Perez-Garcia A, Osman I, Zhu C, Varadarajan N, Restifo NP, Frey AB, Krogsgaard M. Constitutive Lck Activity Drives Sensitivity Differences between CD8+ Memory T Cell Subsets. Journal of Immunology (Baltimore, Md. : 1950). PMID 27271569 DOI: 10.4049/Jimmunol.1600178  0.42
2016 Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM, Shelton TE, et al. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27217459 DOI: 10.1200/Jco.2016.66.7220  0.415
2016 Roychoudhuri R, Clever D, Li P, Wakabayashi Y, Quinn KM, Klebanoff CA, Ji Y, Sukumar M, Eil RL, Yu Z, Spolski R, Palmer DC, Pan JH, Patel SJ, Macallan DC, ... ... Restifo NP, et al. BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers. Nature Immunology. PMID 27158840 DOI: 10.1038/Ni.3441  0.454
2016 Nelson MH, Bowers JS, Bailey SR, Diven MA, Fugle CW, Kaiser AD, Wrzesinski C, Liu B, Restifo NP, Paulos CM. Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning. Journal For Immunotherapy of Cancer. 4: 6. PMID 26885368 DOI: 10.1186/S40425-016-0110-8  0.501
2016 Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nature Medicine. 22: 26-36. PMID 26735408 DOI: 10.1038/Nm.4015  0.501
2016 Roychoudhuri R, Eil RL, Clever D, Klebanoff CA, Sukumar M, Grant FM, Yu Z, Mehta G, Liu H, Jin P, Ji Y, Palmer DC, Pan JH, Chichura A, Crompton JG, ... ... Restifo NP, et al. The transcription factor BACH2 promotes tumor immunosuppression. The Journal of Clinical Investigation. PMID 26731475 DOI: 10.1172/Jci82884  0.537
2016 Ager C, Reilley M, Nicholas C, Bartkowiak T, Jaiswal A, Curran M, Albershardt TC, Bajaj A, Archer JF, Reeves RS, Ngo LY, Berglund P, ter Meulen J, Denis C, Ghadially H, ... ... Restifo N, et al. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two Journal For Immunotherapy of Cancer. 4. DOI: 10.1186/S40425-016-0173-6  0.554
2016 Restifo N. Dissecting Antigen-Specific T-Cell Immunity in Human Cancer and Acquired Resistance to Immunotherapy Blood. 128: SCI-12-SCI-12. DOI: 10.1182/Blood.V128.22.Sci-12.Sci-12  0.547
2016 Vujkovic-Cvijin I, Davis J, Singh R, Lee K, Yu Z, Restifo N, Wei M, Belkaid Y. Abstract A078: Cutaneous microbiota in development of endogenous anti-melanocyte immunity Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-A078  0.404
2016 Wang QJ, Yu Z, Hanada K, Restifo NP, Yang JC. Abstract LB-242: Identification of T-cell receptors targeting KRAS-mutated human tumors Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-242  0.469
2016 Pan JH, Vodnala S, Eil RL, Yu Z, Gartner J, Clever D, Roychoudhuri R, Patel SJ, Klebanoff CA, Sukumar M, Yamamoto T, Restifo NP. Abstract 4034: Immunotherapy generates selective pressure to create an escape tumor with increased susceptibility to treatment with T cell based therapies Cancer Research. 76: 4034-4034. DOI: 10.1158/1538-7445.Am2016-4034  0.499
2016 Eil RL, Roychoudhuri R, Sukumar M, Clever D, Pan JH, Patel S, Palmer DC, Restifo NP. Abstract 1463: Ionic immune suppression within the tumor microenvironment limits T cell effector function Cancer Research. 76: 1463-1463. DOI: 10.1158/1538-7445.Am2016-1463  0.533
2016 Crompton JG, Narayanan M, Cuddapah S, Roychoudhuri R, Ji Y, Yang W, Patel SJ, Sukumar M, Palmer DC, Peng W, Wang E, Marincola FM, Klebanoff CA, Zhao K, Tsang JS, ... ... Restifo NP, et al. Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape Cellular and Molecular Immunology. 13: 502-513. DOI: 10.1038/cmi.2015.32  0.328
2015 Wang QJ, Yu Z, Griffith K, Hanada KI, Restifo NP, Yang JC. Identification of T-cell Receptors Targeting KRAS-mutated Human Tumors. Cancer Immunology Research. PMID 26701267 DOI: 10.1158/2326-6066.Cir-15-0188  0.477
2015 Sukumar M, Liu J, Mehta GU, Patel SJ, Roychoudhuri R, Crompton JG, Klebanoff CA, Ji Y, Li P, Yu Z, Whitehill GD, Clever D, Eil RL, Palmer DC, Mitra S, ... ... Restifo NP, et al. Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. Cell Metabolism. PMID 26674251 DOI: 10.1016/J.Cmet.2015.11.002  0.477
2015 Klebanoff CA, Scott CD, Leonardi AJ, Yamamoto TN, Cruz AC, Ouyang C, Ramaswamy M, Roychoudhuri R, Ji Y, Eil RL, Sukumar M, Crompton JG, Palmer DC, Borman ZA, Clever D, ... ... Restifo NP, et al. Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. The Journal of Clinical Investigation. PMID 26657860 DOI: 10.1172/Jci81217  0.502
2015 Palmer DC, Guittard GC, Franco Z, Crompton JG, Eil RL, Patel SJ, Ji Y, Van Panhuys N, Klebanoff CA, Sukumar M, Clever D, Chichura A, Roychoudhuri R, Varma R, Wang E, ... ... Restifo NP, et al. Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. The Journal of Experimental Medicine. PMID 26527801 DOI: 10.1186/2051-1426-3-S2-P39  0.541
2015 Sukumar M, Roychoudhuri R, Restifo NP. Nutrient Competition: A New Axis of Tumor Immunosuppression. Cell. 162: 1206-8. PMID 26359979 DOI: 10.1016/J.Cell.2015.08.064  0.442
2015 Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, ... ... Restifo NP, et al. Consensus nomenclature for CD8(+) T cell phenotypes in cancer. Oncoimmunology. 4: e998538. PMID 26137416 DOI: 10.1080/2162402X.2014.998538  0.707
2015 Rodriguez-Peña AB, Gomez-Rodriguez J, Kortum RL, Palmer DC, Yu Z, Guittard GC, Wohlfert EA, Silver PB, Misplon JA, Sommers CL, Feigenbaum L, Epstein SL, Caspi RR, Belkaid Y, Restifo NP, et al. Enhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT molecules. Gene Therapy. PMID 26018935 DOI: 10.1038/Gt.2015.48  0.503
2015 Khor B, Gagnon JD, Goel G, Roche MI, Conway KL, Tran K, Aldrich LN, Sundberg TB, Paterson AM, Mordecai S, Dombkowski D, Schirmer M, Tan PH, Bhan AK, Roychoudhuri R, ... Restifo NP, et al. The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells. Elife. 4. PMID 25998054 DOI: 10.7554/Elife.05920  0.392
2015 Beane JD, Lee G, Zheng Z, Mendel M, Abate-Daga D, Bharathan M, Black M, Gandhi N, Yu Z, Chandran S, Giedlin M, Ando D, Miller J, Paschon D, Guschin D, ... ... Restifo NP, et al. Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 25939491 DOI: 10.1038/Mt.2015.71  0.371
2015 Crompton JG, Narayanan M, Cuddapah S, Roychoudhuri R, Ji Y, Yang W, Patel SJ, Sukumar M, Palmer DC, Peng W, Wang E, Marincola FM, Klebanoff CA, Zhao K, Tsang JS, ... ... Restifo NP, et al. Lineage relationship of CD8(+) T cell subsets is revealed by progressive changes in the epigenetic landscape. Cellular & Molecular Immunology. PMID 25914936 DOI: 10.1038/Cmi.2015.32  0.44
2015 Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science (New York, N.Y.). 348: 62-8. PMID 25838374 DOI: 10.1126/Science.Aaa4967  0.463
2015 Stevanovi? S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1543-50. PMID 25823737 DOI: 10.1200/Jco.2014.58.9093  0.419
2015 Roychoudhuri R, Eil RL, Restifo NP. The interplay of effector and regulatory T cells in cancer. Current Opinion in Immunology. 33: 101-11. PMID 25728990 DOI: 10.1016/J.Coi.2015.02.003  0.542
2015 Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, Nahvi AV, Ngo LT, Sherry RM, Phan GQ, Hughes MS, Kammula US, Feldman SA, Toomey MA, Kerkar SP, ... Restifo NP, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2278-88. PMID 25695689 DOI: 10.1158/1078-0432.Ccr-14-2085  0.756
2015 Vahedi G, Kanno Y, Furumoto Y, Jiang K, Parker SC, Erdos MR, Davis SR, Roychoudhuri R, Restifo NP, Gadina M, Tang Z, Ruan Y, Collins FS, Sartorelli V, O'Shea JJ. Super-enhancers delineate disease-associated regulatory nodes in T cells. Nature. 520: 558-62. PMID 25686607 DOI: 10.1038/Nature14154  0.473
2015 Goldszmid RS, Dzutsev A, Viaud S, Zitvogel L, Restifo NP, Trinchieri G. Microbiota modulation of myeloid cells in cancer therapy. Cancer Immunology Research. 3: 103-9. PMID 25660553 DOI: 10.1158/2326-6066.Cir-14-0225  0.486
2015 Ya Z, Hailemichael Y, Overwijk W, Restifo NP. Mouse model for pre-clinical study of human cancer immunotherapy. Current Protocols in Immunology / Edited by John E. Coligan ... [Et Al.]. 108: 20.1.1-43. PMID 25640991 DOI: 10.1002/0471142735.Im2001S108  0.698
2015 Ji Y, Wrzesinski C, Yu Z, Hu J, Gautam S, Hawk NV, Telford WG, Palmer DC, Franco Z, Sukumar M, Roychoudhuri R, Clever D, Klebanoff CA, Surh CD, Waldmann TA, ... Restifo NP, et al. miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines. Proceedings of the National Academy of Sciences of the United States of America. 112: 476-81. PMID 25548153 DOI: 10.1073/Pnas.1422916112  0.416
2015 Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1019-27. PMID 25538264 DOI: 10.1158/1078-0432.Ccr-14-2708  0.785
2015 Roychoudhuri R, Lefebvre F, Honda M, Pan L, Ji Y, Klebanoff CA, Nichols CN, Fourati S, Hegazy AN, Goulet JP, Gattinoni L, Nabel GJ, Gilliet M, Cameron M, Restifo NP, et al. Transcriptional profiles reveal a stepwise developmental program of memory CD8(+) T cell differentiation. Vaccine. 33: 914-23. PMID 25446821 DOI: 10.1016/J.Vaccine.2014.10.007  0.49
2015 Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL, Tran E, Hanada K, Yu Z, Palmer DC, Kerkar SP, Michalek RD, Upham T, Leonardi A, Acquavella N, ... ... Restifo NP, et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Research. 75: 296-305. PMID 25432172 DOI: 10.1158/0008-5472.Can-14-2277  0.506
2015 Acquavella N, Clever D, Yu Z, Roelke-Parker M, Palmer DC, Xi L, Pflicke H, Ji Y, Gros A, Hanada K, Goldlust IS, Mehta GU, Klebanoff CA, Crompton JG, Sukumar M, ... ... Restifo NP, et al. Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunology Research. 3: 37-47. PMID 25358764 DOI: 10.1158/2326-6066.Cir-14-0122  0.546
2015 Khor B, Gagnon JD, Goel G, Roche MI, Conway KL, Tran K, Aldrich LN, Sundberg TB, Paterson AM, Mordecai S, Dombkowski D, Schirmer M, Tan PH, Bhan AK, Roychoudhuri R, ... Restifo NP, et al. Author response: The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells Elife. DOI: 10.7554/Elife.05920.028  0.391
2015 Pan JH, Vodnala S, Eil RL, Yu Z, Gartner JJ, Clever D, Roychoudhuri R, Patel SJ, Klebanoff CA, Sukumar M, Yamamoto T, Restifo NP. Immunotherapy generates selective pressure for acquisition of immunogenic neoantigens in escape tumors Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P68  0.442
2015 Eil RL, Roychoudhuri R, Clever D, Patel S, Sukumar M, Pan JH, Palmer D, Klebanoff CA, Restifo NP. Elevated potassium levels suppress T cell activation within tumors Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P403  0.513
2015 Yamamoto T, Leonardi A, Liu H, Wang E, Gattinoni L, Cruz A, Ouyang C, Siegel R, Restifo N, Klebanoff CA. Fas expression in memory CD8+ T cell subsets augments cellular differentiation and effector function Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P329  0.488
2015 Sukumar M, Liu J, Patel SJ, Klebanoff CA, Mehta G, Roychoudhuri R, Crompton J, Clever D, Gattinoni L, Muranski P, Finkel T, Restifo N. Modulating immunometabolism of tumor specific mouse and human lymphocytes to enhance T cell based therapy for cancer Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P325  0.544
2015 Clever D, Roychoudhuri R, Restifo NP. Inhibition of the T cell oxygen sensing machinery promotes anti-tumor efficacy Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-O1  0.565
2015 Klemen N, Vizcardo R, Tran L, Restifo NP. Precocious Differentiation of Somatic and Pluripotent Stem Cells Bearing Pre-Arranged TCR Blood. 126: 847-847. DOI: 10.1182/Blood.V126.23.847.847  0.481
2015 Patel S, Sukumar M, Palmer D, Roychoudhari R, Roy R, Nussenzweig A, Restifo N. Abstract 1347: Genomic stress in antigen experienced T-lymphocytes Cancer Research. 75: 1347-1347. DOI: 10.1158/1538-7445.Am2015-1347  0.501
2015 Beane JD, Lee G, Zheng Z, Gandhi N, Abate-Daga D, Bharathan M, Black M, Mendel M, Yu Z, Kassim SH, Chandran S, Giedlin MA, Ando D, Rebar E, Reik A, ... ... Restifo NP, et al. 77. Clinical Scale Zinc Finger Nuclease (ZFN)-Driven Gene-Editing of PD-1 in Tumor Infiltrating Lymphocytes (TIL) for the Potential Treatment of Metastatic Melanoma Molecular Therapy. 23: S33-S34. DOI: 10.1016/S1525-0016(16)33682-6  0.757
2014 Stevanovic S, Draper L, Somerville R, Wunderlich J, Restifo NP, Sherry R, Giao PQ, Kammula US, Yang JC, Rosenberg SA. HPV-targeted tumor-infiltrating lymphocytes for cervical cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: LBA3008. PMID 28141973 DOI: 10.1200/Jco.2014.32.18_Suppl.Lba3008  0.384
2014 Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, ... ... Restifo NP, et al. Classification of current anticancer immunotherapies. Oncotarget. 5: 12472-508. PMID 25537519 DOI: 10.18632/Oncotarget.2998  0.431
2014 Klebanoff CA, Yamamoto TN, Restifo NP. Immunotherapy: Treatment of aggressive lymphomas with anti-CD19 CAR T cells. Nature Reviews. Clinical Oncology. 11: 685-6. PMID 25384948 DOI: 10.1038/Nrclinonc.2014.190  0.481
2014 Restifo NP. Big bang theory of stem-like T cells confirmed. Blood. 124: 476-7. PMID 25061170 DOI: 10.1182/Blood-2014-06-578989  0.458
2014 Ji Y, Abrams N, Zhu W, Salinas E, Yu Z, Palmer DC, Jailwala P, Franco Z, Roychoudhuri R, Stahlberg E, Gattinoni L, Restifo NP. Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing. Plos One. 9: e96650. PMID 24827921 DOI: 10.1371/Journal.Pone.0096650  0.353
2014 Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U, Restifo NP, Feldman SA, Rosenberg SA, Morgan RA. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Human Gene Therapy. 25: 1003-12. PMID 24694017 DOI: 10.1089/Hum.2013.209  0.475
2014 Crompton JG, Clever D, Vizcardo R, Rao M, Restifo NP. Reprogramming antitumor immunity. Trends in Immunology. 35: 178-85. PMID 24661777 DOI: 10.1016/J.It.2014.02.003  0.329
2014 Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nature Reviews. Immunology. 14: 24-35. PMID 24336101 DOI: 10.1038/Nri3567  0.406
2014 Crompton JG, Sukumar M, Restifo NP. Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. Immunological Reviews. 257: 264-76. PMID 24329803 DOI: 10.1111/Imr.12135  0.535
2014 Church SE, Jensen SM, Antony PA, Restifo NP, Fox BA. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. European Journal of Immunology. 44: 69-79. PMID 24114780 DOI: 10.1002/Eji.201343718  0.499
2014 Palmer D, Guittard G, Patel S, Samelson LE, Restifo NP. Cish attenuates proximal TCR-signaling and CD8+ T cell immunity Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P32  0.524
2014 Zhong S, Malecek K, Moogk D, Johnson LA, Yu Z, Grigoryan A, Vega-Saenz de Miera E, Darvishian F, Gu W, McGary K, Huang K, Boyer J, Corse E, Yongzhao S, Rosenberg SA, ... Restifo NP, et al. Engineering the immune response to "self" for effective cancer immunotherapy Journal For Immunotherapy of Cancer. 2: P22. DOI: 10.1186/2051-1426-2-S3-P22  0.454
2014 Beane JD, Lee GK, Zheng Z, Gandhi N, Abate-Daga D, Bharathan M, Black M, Mendel M, Yu Z, Kassim SH, Chandran S, Giedlin M, Ando D, Rebar E, Reik A, ... ... Restifo NP, et al. Clinical scale zinc finger nuclease (ZFN)-driven gene-editing of PD-1 in tumor infiltrating lymphocytes (TIL) for the potential treatment of metastatic melanoma Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P2  0.704
2014 Sukumar M, Liu J, Mehta G, Gattinoni L, Finkel T, Restifo N. Modulating immunometabolism of tumor specific CD8 T cells to enhance T cell based therapy for cancer Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-O2  0.522
2014 Bot A, Chiriva-Internati M, Cornforth A, Czerniecki BJ, Ferrone S, Geles K, Greenberg PD, Hurt E, Koya RC, Manjili MH, Matsui W, Morgan RA, Palena CM, Powell Jr DJ, Restifo NP, et al. Stem cells and cancer immunotherapy: Arrowhead’s 2nd annual cancer immunotherapy conference Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-6  0.348
2014 Restifo NP. Abstract SY31-02: Building highly effective anti-tumor T cells Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Sy31-02  0.504
2013 Overwijk WW, Wang E, Marincola FM, Rammensee HG, Restifo NP. Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. Journal For Immunotherapy of Cancer. 1: 11. PMID 24829748 DOI: 10.1186/2051-1426-1-11  0.654
2013 Restifo NP, Gattinoni L. Lineage relationship of effector and memory T cells. Current Opinion in Immunology. 25: 556-63. PMID 24148236 DOI: 10.1016/J.Coi.2013.09.003  0.443
2013 Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nature Biotechnology. 31: 999-1008. PMID 24142051 DOI: 10.1038/Nbt.2725  0.501
2013 Restifo NP. A "big data" view of the tumor "immunome". Immunity. 39: 631-2. PMID 24138879 DOI: 10.1016/J.Immuni.2013.10.002  0.442
2013 Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, Roychoudhuri R, Palmer DC, Muranski P, Karoly ED, Mohney RP, Klebanoff CA, Lal A, Finkel T, Restifo NP, et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. The Journal of Clinical Investigation. 123: 4479-88. PMID 24091329 DOI: 10.1172/Jci69589  0.454
2013 Klebanoff CA, Spencer SP, Torabi-Parizi P, Grainger JR, Roychoudhuri R, Ji Y, Sukumar M, Muranski P, Scott CD, Hall JA, Ferreyra GA, Leonardi AJ, Borman ZA, Wang J, Palmer DC, ... ... Restifo NP, et al. Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells. The Journal of Experimental Medicine. 210: 1961-76. PMID 23999499 DOI: 10.1084/Jem.20122508  0.357
2013 Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Klebanoff CA, Bonelli M, Sciumè G, Zare H, Vahedi G, Dema B, Yu Z, Liu H, Takahashi H, Rao M, Muranski P, ... ... Restifo NP, et al. BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature. 498: 506-10. PMID 23728300 DOI: 10.1038/Nature12199  0.46
2013 Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP, Rosenberg SA. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. The Journal of Experimental Medicine. 210: 1125-35. PMID 23712432 DOI: 10.1084/Jem.20130110  0.529
2013 Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2152-9. PMID 23650429 DOI: 10.1200/Jco.2012.46.6441  0.465
2013 Chinnasamy D, Tran E, Yu Z, Morgan RA, Restifo NP, Rosenberg SA. Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. Cancer Research. 73: 3371-80. PMID 23633494 DOI: 10.1158/0008-5472.Can-12-3913  0.547
2013 Dudda JC, Salaun B, Ji Y, Palmer DC, Monnot GC, Merck E, Boudousquie C, Utzschneider DT, Escobar TM, Perret R, Muljo SA, Hebeisen M, Rufer N, Zehn D, Donda A, ... Restifo NP, et al. MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity. 38: 742-53. PMID 23601686 DOI: 10.1016/J.Immuni.2012.12.006  0.429
2013 Zhong S, Malecek K, Johnson LA, Yu Z, Vega-Saenz de Miera E, Darvishian F, McGary K, Huang K, Boyer J, Corse E, Shao Y, Rosenberg SA, Restifo NP, Osman I, Krogsgaard M. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proceedings of the National Academy of Sciences of the United States of America. 110: 6973-8. PMID 23576742 DOI: 10.1073/pnas.1221609110  0.54
2013 Kerkar SP, Leonardi AJ, van Panhuys N, Zhang L, Yu Z, Crompton JG, Pan JH, Palmer DC, Morgan RA, Rosenberg SA, Restifo NP. Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1369-77. PMID 23568260 DOI: 10.1038/Mt.2013.58  0.517
2013 Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, ... ... Restifo NP, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 133-51. PMID 23377668 DOI: 10.1097/Cji.0B013E3182829903  0.347
2013 Gattinoni L, Restifo NP. Moving T memory stem cells to the clinic. Blood. 121: 567-8. PMID 23349370 DOI: 10.1182/Blood-2012-11-468660  0.382
2013 Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood. 121: 2402-14. PMID 23325835 DOI: 10.1182/Blood-2012-09-378653  0.454
2013 Hanada K, Restifo NP. Double or nothing on cancer immunotherapy. Nature Biotechnology. 31: 33-4. PMID 23302931 DOI: 10.1038/Nbt.2471  0.542
2013 Crompton JG, Rao M, Restifo NP. Memoirs of a reincarnated T cell. Cell Stem Cell. 12: 6-8. PMID 23290132 DOI: 10.1016/J.Stem.2012.12.009  0.437
2013 Lugli E, Dominguez MH, Gattinoni L, Chattopadhyay PK, Bolton DL, Song K, Klatt NR, Brenchley JM, Vaccari M, Gostick E, Price DA, Waldmann TA, Restifo NP, Franchini G, Roederer M. Superior T memory stem cell persistence supports long-lived T cell memory. The Journal of Clinical Investigation. 123: 594-9. PMID 23281401 DOI: 10.1172/Jci66327  0.44
2013 Lugli E, Gattinoni L, Roberto A, Mavilio D, Price DA, Restifo NP, Roederer M. Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. Nature Protocols. 8: 33-42. PMID 23222456 DOI: 10.1038/Nprot.2012.143  0.456
2013 Yang S, Ji Y, Gattinoni L, Zhang L, Yu Z, Restifo NP, Rosenberg SA, Morgan RA. Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunology, Immunotherapy : Cii. 62: 727-36. PMID 23207483 DOI: 10.1007/S00262-012-1378-2  0.459
2013 Zhang L, Yu Z, Muranski P, Palmer DC, Restifo NP, Rosenberg SA, Morgan RA. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Therapy. 20: 575-80. PMID 22972494 DOI: 10.1038/Gt.2012.75  0.473
2013 Klebanoff CA, Spencer S, Roychoudhuri R, Ji Y, Sukumar M, Muranski P, Napoli JL, Gattinoni L, Belkaid Y, Restifo NP. Induction of an acute vitamin A-deficient state following total body irradiation impairs anti-tumor immunity by altering the homeostasis of pre-cDC derived dendritic cells Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P121  0.457
2013 Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Bonelli M, Klebanoff C, Sartorelli V, Kanno Y, Gattinoni L, Wang E, Liu H, Marincola F, Kazuhiko I, O’Shea J, Restifo NP. BACH2 represses effector programmes to stabilize Treg-mediated immune homeostasis - a new target in tumor immunotherapy? Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-O14  0.493
2013 Sukumar M, Liu J, Crompton J, Rao M, Ji Y, Finkel T, Gattinoni L, Restifo N. Mitochondrial activity regulates T cell memory, self renewal and anti tumor function in CD8+ T cells Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-O11  0.49
2013 Stroncek DF, Melief CJ, Castiello L, Cesano A, Cheever MA, Civini S, Comin-Anduix B, Gajewski TF, Greenberg PD, Kalinski P, Kaufman HL, Kershaw MH, Khleif SN, Marincola F, Merritt W, ... ... Restifo NP, et al. Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-4  0.446
2013 Restifo NP. Abstract IA20: Sugar high: Glycolytic flux wrecks stem-cell like T cells. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-Ia20  0.548
2013 Abate-Daga D, Lagisetty KH, Gattinoni L, Yu Z, Restifo NP, Rosenberg SA, Morgan RA. Abstract 3966: Development of a fully-human chimeric antigen receptor against PSCA for the treatment of pancreatic cancer. Cancer Research. 73: 3966-3966. DOI: 10.1158/1538-7445.Am2013-3966  0.418
2013 Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Bonelli M, Sciume G, Zare H, Vahedi G, Klebanoff C, Sartorelli V, Kanno Y, Gattinoni L, Nakamura A, Muto A, O’Shea J, ... Restifo N, et al. 217 Cytokine. 63: 294. DOI: 10.1016/J.Cyto.2013.06.220  0.487
2012 Klebanoff CA, Gattinoni L, Restifo NP. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? Journal of Immunotherapy (Hagerstown, Md. : 1997). 35: 651-60. PMID 23090074 DOI: 10.1097/Cji.0B013E31827806E6  0.491
2012 Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nature Reviews. Cancer. 12: 671-84. PMID 22996603 DOI: 10.1038/Nrc3322  0.458
2012 Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, Aghamolla T, Alvarez-Downing MM, Lee CC, Singh S, Li T, Dudley ME, Restifo NP, Rosenberg SA, Kammula US. The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Science Translational Medicine. 4: 149ra120. PMID 22932225 DOI: 10.1126/Scitranslmed.3004306  0.52
2012 Zou W, Restifo NP. Nine lives for TH9s? Nature Medicine. 18: 1177-8. PMID 22869182 DOI: 10.1038/Nm.2868  0.502
2012 Jensen SM, Twitty CG, Maston LD, Antony PA, Lim M, Hu HM, Petrausch U, Restifo NP, Fox BA. Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence. Journal of Immunology (Baltimore, Md. : 1950). 189: 767-76. PMID 22723522 DOI: 10.4049/Jimmunol.1103822  0.561
2012 Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Research. 72: 3125-30. PMID 22721837 DOI: 10.1158/0008-5472.Can-11-4094  0.51
2012 Kerkar SP, Restifo NP. The power and pitfalls of IL-12. Blood. 119: 4096-7. PMID 22555659 DOI: 10.1182/Blood-2012-03-415018  0.467
2012 Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Reviews. Immunology. 12: 269-81. PMID 22437939 DOI: 10.1038/Nri3191  0.491
2012 Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, Flynn P, Gattinoni L, Heath JR, Kalos M, Marincola FM, Miller JS, Mostoslavsky G, Powell DJ, Rao M, Restifo NP, et al. New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. Journal of Translational Medicine. 10: 48. PMID 22420641 DOI: 10.1186/1479-5876-10-48  0.496
2012 Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP, Rosenberg SA. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1672-83. PMID 22291136 DOI: 10.1158/1078-0432.Ccr-11-3050  0.455
2012 Lugli DE, Gattinoni L, Restifo NP, Roederer M. 141 The Role of T Memory Stem Cells Jaids Journal of Acquired Immune Deficiency Syndromes. 59: 59. DOI: 10.1097/01.Qai.0000413760.15503.00  0.37
2011 Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DN, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, ... Restifo NP, et al. T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 620-626. PMID 28160822 DOI: 10.1038/mt.2010.272  0.41
2011 Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ, Roychoudhuri R, Ferreyra GA, Shen W, Durum SK, Feigenbaum L, ... ... Restifo NP, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity. 35: 972-85. PMID 22177921 DOI: 10.1016/J.Immuni.2011.09.019  0.442
2011 Ji Y, Pos Z, Rao M, Klebanoff CA, Yu Z, Sukumar M, Reger RN, Palmer DC, Borman ZA, Muranski P, Wang E, Schrump DS, Marincola FM, Restifo NP, Gattinoni L. Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nature Immunology. 12: 1230-7. PMID 22057288 DOI: 10.1038/Ni.2153  0.43
2011 Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, Leonardi AJ, Morgan RA, Wang E, Marincola FM, Trinchieri G, Rosenberg SA, Restifo NP. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. The Journal of Clinical Investigation. 121: 4746-57. PMID 22056381 DOI: 10.1172/Jci58814  0.546
2011 Ascierto ML, Worschech A, Yu Z, Adams S, Reinboth J, Chen NG, Pos Z, Roychoudhuri R, Di Pasquale G, Bedognetti D, Uccellini L, Rossano F, Ascierto PA, Stroncek DF, Restifo NP, et al. Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. Bmc Cancer. 11: 451. PMID 22011439 DOI: 10.1186/1471-2407-11-451  0.404
2011 Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, Wang E, Douek DC, Price DA, June CH, Marincola FM, ... ... Restifo NP, et al. A human memory T cell subset with stem cell-like properties. Nature Medicine. 17: 1290-7. PMID 21926977 DOI: 10.1038/Nm.2446  0.484
2011 Liu Y, Tian X, Leitner WW, Aldridge ME, Zheng J, Yu Z, Restifo NP, Weiss R, Scheiblhofer S, Xie C, Sun R, Cheng G, Zeng G. Polymeric structure and host toll-like receptor 4 dictate immunogenicity of NY-ESO-1 antigen in vivo Journal of Biological Chemistry. 286: 37077-37084. PMID 21900253 DOI: 10.1074/Jbc.M111.280123  0.451
2011 Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, Borman ZA, Kerkar SP, Scott CD, Finkelstein SE, Rosenberg SA, Restifo NP. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5343-52. PMID 21737507 DOI: 10.1158/1078-0432.Ccr-11-0503  0.562
2011 Kerkar SP, Sanchez-Perez L, Yang S, Borman ZA, Muranski P, Ji Y, Chinnasamy D, Kaiser AD, Hinrichs CS, Klebanoff CA, Scott CD, Gattinoni L, Morgan RA, Rosenberg SA, Restifo NP. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 343-52. PMID 21499127 DOI: 10.1097/Cji.0B013E3182187600  0.543
2011 Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4550-7. PMID 21498393 DOI: 10.1158/1078-0432.Ccr-11-0116  0.432
2011 Amos SM, Pegram HJ, Westwood JA, John LB, Devaud C, Clarke CJ, Restifo NP, Smyth MJ, Darcy PK, Kershaw MH. Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunology, Immunotherapy : Cii. 60: 671-83. PMID 21327636 DOI: 10.1007/S00262-011-0984-8  0.511
2011 Yang S, Gattinoni L, Luca G, Liu F, Ji Y, Yu Z, Restifo NP, Rosenberg SA, Morgan RA. In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. Cancer Immunology, Immunotherapy : Cii. 60: 739-49. PMID 21305379 DOI: 10.1007/S00262-011-0977-7  0.549
2011 Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, Rosenberg SA, Morgan RA. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 751-9. PMID 21285960 DOI: 10.1038/Mt.2010.313  0.443
2011 Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 917-24. PMID 21282551 DOI: 10.1200/Jco.2010.32.2537  0.553
2011 Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunological Reviews. 239: 27-44. PMID 21198663 DOI: 10.1111/J.1600-065X.2010.00979.X  0.548
2011 Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, ... Restifo NP, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 620-6. PMID 21157437 DOI: 10.1038/Mt.2010.272  0.506
2011 Chinnasamy N, Wargo JA, Yu Z, Rao M, Frankel TL, Riley JP, Hong JJ, Parkhurst MR, Feldman SA, Schrump DS, Restifo NP, Robbins PF, Rosenberg SA, Morgan RA. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. Journal of Immunology (Baltimore, Md. : 1950). 186: 685-96. PMID 21149604 DOI: 10.4049/Jimmunol.1001775  0.391
2011 Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, Klebanoff CA, Johnson LA, Kerkar SP, Yang S, Muranski P, Palmer DC, Scott CD, Morgan RA, Robbins PF, ... ... Restifo NP, et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood. 117: 808-14. PMID 20971955 DOI: 10.1182/Blood-2010-05-286286  0.504
2011 Zou W, Restifo NP. Erratum: TH 17 cells in tumour immunity and immunotherapy (Nature Reviews Immunology (2010) 10 (248-256)) Nature Reviews Immunology. 11: 565-565. DOI: 10.1038/Nri3029  0.353
2011 Scott CD, Klebanoff CA, Roychoudhuri R, Kerkar SP, Borman ZA, Rosenberg SA, Restifo NP. Activation of naïve CD8+ T cells by memory cells impairs antitumor immunity in adoptive cell transfer Journal of the American College of Surgeons. 213: S104-S105. DOI: 10.1016/J.Jamcollsurg.2011.06.233  0.484
2011 Yang S, Gattinoni L, Liu F, Ji Y, Yu Z, Restifo NP, Rosenberg SA, Morgan RA. Erratum to: In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells Cancer Immunology, Immunotherapy. 60: 751-751. DOI: 10.1007/S00262-011-0994-6  0.548
2010 Ha SP, Klemen ND, Kinnebrew GH, Brandmaier AG, Marsh J, Hangoc G, Palmer DC, Restifo NP, Cornetta K, Broxmeyer HE, Touloukian CE. Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity. The Journal of Clinical Investigation. 120: 4273-88. PMID 21084750 DOI: 10.1172/Jci43274  0.502
2010 Restifo NP. Can antitumor immunity help to explain "oncogene addiction"? Cancer Cell. 18: 403-5. PMID 21075303 DOI: 10.1016/J.Ccr.2010.11.002  0.437
2010 Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, Feldman SA, Restifo NP, Rosenberg SA. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. The Journal of Clinical Investigation. 120: 3953-68. PMID 20978347 DOI: 10.1172/Jci43490  0.539
2010 Gattinoni L, Ji Y, Restifo NP. Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4695-701. PMID 20688898 DOI: 10.1158/1078-0432.Ccr-10-0356  0.446
2010 Rausch MP, Irvine KR, Antony PA, Restifo NP, Cresswell P, Hastings KT. GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1. Journal of Immunology (Baltimore, Md. : 1950). 185: 2828-35. PMID 20668223 DOI: 10.4049/Jimmunol.1000945  0.495
2010 Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich JR, Prieto PA, Hong JJ, Langan RC, et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 6122-31. PMID 20668005 DOI: 10.1158/1078-0432.Ccr-10-1297  0.451
2010 Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, Palmer DC, Reger RN, Borman ZA, Zhang L, Morgan RA, Gattinoni L, Rosenberg SA, Trinchieri G, Restifo NP. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Research. 70: 6725-34. PMID 20647327 DOI: 10.1158/0008-5472.Can-10-0735  0.539
2010 Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. 116: 3875-86. PMID 20631379 DOI: 10.1182/Blood-2010-01-265041  0.488
2010 Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Research. 70: 6171-80. PMID 20631075 DOI: 10.1158/0008-5472.Can-10-0153  0.451
2010 Rosenberg SA, Yang JC, Kammula US, Hughes MS, Restifo NP, Schwarz SL, Morton KE, Laurencot CM, Sherry RM. Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 626-9. PMID 20551834 DOI: 10.1097/Cji.0B013E3181Dac9De  0.407
2010 Frankel TL, Burns WR, Peng PD, Yu Z, Chinnasamy D, Wargo JA, Zheng Z, Restifo NP, Rosenberg SA, Morgan RA. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. Journal of Immunology (Baltimore, Md. : 1950). 184: 5988-98. PMID 20427771 DOI: 10.4049/Jimmunol.1000189  0.494
2010 Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nature Reviews. Immunology. 10: 248-56. PMID 20336152 DOI: 10.1038/Nri2742  0.477
2010 Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, Muranski P, Restifo NP, Antony PA. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. The Journal of Experimental Medicine. 207: 651-67. PMID 20156973 DOI: 10.1084/Jem.20091921  0.577
2010 Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, Restifo NP, Allison JP. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. The Journal of Experimental Medicine. 207: 637-50. PMID 20156971 DOI: 10.1084/Jem.20091918  0.566
2010 Flatz L, Hegazy AN, Bergthaler A, Verschoor A, Claus C, Fernandez M, Gattinoni L, Johnson S, Kreppel F, Kochanek S, Broek Mv, Radbruch A, Lévy F, Lambert PH, Siegrist CA, ... Restifo NP, et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nature Medicine. 16: 339-45. PMID 20139992 DOI: 10.1038/Nm.2104  0.491
2010 Bolinger B, Engeler D, Krebs P, Miller S, Firner S, Hoffmann M, Palmer DC, Restifo NP, Tian Y, Clavien PA, Ludewig B. IFN-gamma-receptor signaling ameliorates transplant vasculopathy through attenuation of CD8+ T-cell-mediated injury of vascular endothelial cells. European Journal of Immunology. 40: 733-43. PMID 20049875 DOI: 10.1002/Eji.200939706  0.422
2010 Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 1-7. PMID 19952961 DOI: 10.1097/Cji.0B013E3181B88Ffc  0.535
2010 Restifo NP, Sukumar M, Gattinoni L. Improving Adoptive Immunotherapy Using Less-Differentiated T Cells Blood. 116: SCI-49-SCI-49. DOI: 10.1182/Blood.V116.21.Sci-49.Sci-49  0.561
2010 Muranski P, Borman Z, Kerkar S, Ji Y, Gattinoni L, Robert RN, Sanchez-Perez L, Christopher KA, Yu Z, Steven KJ, Ferreyra G, Danner RL, Restifo NP. Th17-Derived Memory Cells Are Long-Lived and Retain a Stem-Like Molecular Signature Blood. 116: 1018-1018. DOI: 10.1182/Blood.V116.21.1018.1018  0.476
2010 Restifo NP, Gattinoni L. Abstract SY03-02: Wnt signaling generates “stem-like” self-renewing T cells that can eradicate tumors Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Sy03-02  0.569
2010 Gattinoni L, Ji Y, Restifo NP. Reply to: Β-catenin does not regulate memory T cell phenotype Nature Medicine. 16: 514-515. DOI: 10.1038/Nm0510-514  0.349
2009 Gattinoni L, Klebanoff CA, Restifo NP. Pharmacologic induction of CD8+ T cell memory: better living through chemistry. Science Translational Medicine. 1: 11ps12. PMID 20371454 DOI: 10.1126/Scitranslmed.3000302  0.451
2009 Palmer DC, Restifo NP. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends in Immunology. 30: 592-602. PMID 19879803 DOI: 10.1016/J.It.2009.09.009  0.478
2009 Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 31: 787-98. PMID 19879162 DOI: 10.1016/J.Immuni.2009.09.014  0.736
2009 Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC, Ji Y, Reger RN, Leonard WJ, Danner RL, ... ... Restifo NP, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America. 106: 17469-74. PMID 19805141 DOI: 10.1073/Pnas.0907448106  0.525
2009 Brandmaier AG, Leitner WW, Ha SP, Sidney J, Restifo NP, Touloukian CE. High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction. Journal of Immunotherapy (Hagerstown, Md. : 1997). 32: 677-88. PMID 19561540 DOI: 10.1097/Cji.0B013E3181Ab1824  0.547
2009 Klebanoff CA, Yu Z, Hwang LN, Palmer DC, Gattinoni L, Restifo NP. Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. Blood. 114: 1776-83. PMID 19561320 DOI: 10.1182/Blood-2008-12-192419  0.553
2009 Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Garvin LM, Paulos CM, Muranski P, Restifo NP. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nature Medicine. 15: 808-13. PMID 19525962 DOI: 10.1038/Nm.1982  0.438
2009 Tewalt EF, Grant JM, Granger EL, Palmer DC, Heuss ND, Gregerson DS, Restifo NP, Norbury CC. Viral sequestration of antigen subverts cross presentation to CD8(+) T cells. Plos Pathogens. 5: e1000457. PMID 19478869 DOI: 10.1371/Journal.Ppat.1000457  0.438
2009 Hinrichs CS, Kaiser A, Paulos CM, Cassard L, Sanchez-Perez L, Heemskerk B, Wrzesinski C, Borman ZA, Muranski P, Restifo NP. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood. 114: 596-9. PMID 19471017 DOI: 10.1182/Blood-2009-02-203935  0.515
2009 Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 114: 535-46. PMID 19451549 DOI: 10.1182/Blood-2009-03-211714  0.484
2009 Yeh S, Karne NK, Kerkar SP, Heller CK, Palmer DC, Johnson LA, Li Z, Bishop RJ, Wong WT, Sherry RM, Yang JC, Dudley ME, Restifo NP, Rosenberg SA, Nussenblatt RB. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology. 116: 981-989.e1. PMID 19410956 DOI: 10.1016/J.Ophtha.2008.12.004  0.454
2009 Schumacher TN, Restifo NP. Adoptive T cell therapy of cancer Current Opinion in Immunology. 21: 187-189. PMID 19328668 DOI: 10.1016/J.Coi.2009.03.006  0.579
2009 Muranski P, Restifo NP. Adoptive immunotherapy of cancer using CD4+ T cells Current Opinion in Immunology. 21: 200-208. PMID 19285848 DOI: 10.1016/J.Coi.2009.02.004  0.54
2009 Muranski P, Kerkar SP, Borman ZA, Reger R, Sanchez-Perez L, Hinrichs CS, Yu Z, Palmer DC, Gattinoni L, Restifo NP. IL-17A-Expressing CD4+ T Cells Must Acquire the Expression of T-Bet and IFN-γto Destroy Tumor Cells In Vivo. Blood. 114: 468-468. DOI: 10.1182/Blood.V114.22.468.468  0.528
2009 Muranski P, Restifo NP. Does IL-17 promote tumor growth? Blood. 114: 231-232. DOI: 10.1182/Blood-2009-04-215541  0.325
2008 Robila V, Ostankovitch M, Altrich-Vanlith ML, Theos AC, Drover S, Marks MS, Restifo N, Engelhard VH. MHC class II presentation of gp100 epitopes in melanoma cells requires the function of conventional endosomes and is influenced by melanosomes. Journal of Immunology (Baltimore, Md. : 1950). 181: 7843-52. PMID 19017974 DOI: 10.4049/Jimmunol.181.11.7843  0.302
2008 Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5233-9. PMID 18809613 DOI: 10.1200/Jco.2008.16.5449  0.347
2008 Boni A, Muranski P, Cassard L, Wrzesinski C, Paulos CM, Palmer DC, Gattinoni L, Hinrichs CS, Chan CC, Rosenberg SA, Restifo NP. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood. 112: 4746-54. PMID 18799724 DOI: 10.1182/Blood-2008-07-169797  0.536
2008 Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM, Rosenberg SA. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5610-8. PMID 18765555 DOI: 10.1158/1078-0432.Ccr-08-0116  0.323
2008 Ahn S, Lee G, Yang SJ, Lee D, Lee S, Shin HS, Kim MC, Lee KN, Palmer DC, Theoret MR, Jenkinson EJ, Anderson G, Restifo NP, Kim MG. TSCOT+ thymic epithelial cell-mediated sensitive CD4 tolerance by direct presentation. Plos Biology. 6: e191. PMID 18684012 DOI: 10.1371/Journal.Pbio.0060191  0.504
2008 Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, Powell DJ, Klebanoff CA, Finkelstein SE, Fariss RN, Yu Z, Nussenblatt RB, Rosenberg SA, Restifo NP. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proceedings of the National Academy of Sciences of the United States of America. 105: 8061-6. PMID 18523011 DOI: 10.1073/Pnas.0710929105  0.527
2008 Yang S, Cohen CJ, Peng PD, Zhao Y, Cassard L, Yu Z, Zheng Z, Jones S, Restifo NP, Rosenberg SA, Morgan RA. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Therapy. 15: 1411-23. PMID 18496571 DOI: 10.1038/Gt.2008.90  0.42
2008 Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nature Reviews. Cancer. 8: 299-308. PMID 18354418 DOI: 10.1038/Nrc2355  0.368
2008 Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, ... ... Restifo NP, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 112: 362-73. PMID 18354038 DOI: 10.1182/Blood-2007-11-120998  0.558
2008 Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ, Restifo NP. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood. 111: 5326-33. PMID 18276844 DOI: 10.1182/Blood-2007-09-113050  0.432
2008 Bolinger B, Krebs P, Tian Y, Engeler D, Scandella E, Miller S, Palmer DC, Restifo NP, Clavien PA, Ludewig B. Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigen. Blood. 111: 4588-95. PMID 18195091 DOI: 10.1182/Blood-2007-09-114769  0.475
2008 Abad JD, Wrzensinski C, Overwijk W, De Witte MA, Jorritsma A, Hsu C, Gattinoni L, Cohen CJ, Paulos CM, Palmer DC, Haanen JB, Schumacher TN, Rosenberg SA, Restifo NP, Morgan RA. T-cell receptor gene therapy of established tumors in a murine melanoma model. Journal of Immunotherapy (Hagerstown, Md. : 1997). 31: 1-6. PMID 18157006 DOI: 10.1097/Cji.0B013E31815C193F  0.726
2008 Muranski P, Hinrichs CS, Sanchez-Perez L, Boni A, Kerkar S, Gattinoni L, Yu Z, Restifo NP. Treatment of Large Established Murine Melanoma with Th17 Polarized CD4+ T Helper Cells Genetically Engineered to Express MHC Class IIRestricted T Cell Receptor Blood. 112: 3911-3911. DOI: 10.1182/Blood.V112.11.3911.3911  0.54
2008 Ha SP, Cornetta K, Broxmeyer HE, Restifo NP, Touloukian CE. 65. CD4+ T Cell Immunity Following Gene Transfer Into Hematopoietic Stem Cells Journal of Surgical Research. 144: 204-205. DOI: 10.1016/J.Jss.2007.12.075  0.473
2007 Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z, Antony PA, Gattinoni L, Rosenberg SA, Restifo NP. Toll-like receptors in tumor immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5280-9. PMID 17875756 DOI: 10.1158/1078-0432.Ccr-07-1378  0.527
2007 Borbulevych OY, Insaidoo FK, Baxter TK, Powell DJ, Johnson LA, Restifo NP, Baker BM. Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. Journal of Molecular Biology. 372: 1123-36. PMID 17719062 DOI: 10.1016/J.Jmb.2007.07.025  0.427
2007 Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z, Gattinoni L, Antony PA, Rosenberg SA, Restifo NP. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. The Journal of Clinical Investigation. 117: 2197-204. PMID 17657310 DOI: 10.1172/Jci32205  0.496
2007 Zhao Y, Parkhurst MR, Zheng Z, Cohen CJ, Riley JP, Gattinoni L, Restifo NP, Rosenberg SA, Morgan RA. Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Research. 67: 2425-9. PMID 17363559 DOI: 10.1158/0008-5472.Can-06-3977  0.581
2007 Wrzesinski C, Paulos CM, Gattinoni L, Palmer DC, Kaiser A, Yu Z, Rosenberg SA, Restifo NP. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. The Journal of Clinical Investigation. 117: 492-501. PMID 17273561 DOI: 10.1172/Jci30414  0.564
2007 Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z, Gattinoni L, Antony PA, Rosenberg SA, Restifo NP. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling Journal of Clinical Investigation. 117: 3140-3140. DOI: 10.1172/Jci32205C1  0.479
2006 Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, Restifo NP. Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nature Clinical Practice. Oncology. 3: 668-81. PMID 17139318 DOI: 10.1038/Ncponc0666  0.503
2006 Lee CH, Kakinuma T, Wang J, Zhang H, Palmer DC, Restifo NP, Hwang ST. Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Molecular Cancer Therapeutics. 5: 2592-9. PMID 17041104 DOI: 10.1158/1535-7163.Mct-06-0310  0.521
2006 Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (New York, N.Y.). 314: 126-9. PMID 16946036 DOI: 10.1126/Science.1129003  0.489
2006 Gattinoni L, Ranganathan A, Surman DR, Palmer DC, Antony PA, Theoret MR, Heimann DM, Rosenberg SA, Restifo NP. CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. Blood. 108: 3818-23. PMID 16882704 DOI: 10.1182/Blood-2006-07-034066  0.534
2006 Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy Immunological Reviews. 211: 214-224. PMID 16824130 DOI: 10.1111/J.0105-2896.2006.00391.X  0.493
2006 Donohue KB, Grant JM, Tewalt EF, Palmer DC, Theoret MR, Restifo NP, Norbury CC. Cross-priming utilizes antigen not available to the direct presentation pathway. Immunology. 119: 63-73. PMID 16764686 DOI: 10.1111/J.1365-2567.2006.02406.X  0.49
2006 Leitner WW, Bergmann-Leitner ES, Hwang LN, Restifo NP. Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine. 24: 5110-8. PMID 16725231 DOI: 10.1016/J.Vaccine.2006.04.059  0.398
2006 Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, Sakaguchi S, Houghton AN. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Research. 66: 4904-12. PMID 16651447 DOI: 10.1158/0008-5472.Can-05-2813  0.552
2006 Lindsey KR, Gritz L, Sherry R, Abati A, Fetsch PA, Goldfeder LC, Gonzales MI, Zinnack KA, Rogers-Freezer L, Haworth L, Mavroukakis SA, White DE, Steinberg SM, Restifo NP, Panicali DL, et al. Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2526-37. PMID 16638862 DOI: 10.1158/1078-0432.Ccr-05-2061  0.329
2006 Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nature Reviews. Immunology. 6: 383-93. PMID 16622476 DOI: 10.1038/Nri1842  0.473
2006 Antony PA, Paulos CM, Ahmadzadeh M, Akpinarli A, Palmer DC, Sato N, Kaiser A, Hinrichs CS, Heinrichs C, Klebanoff CA, Tagaya Y, Restifo NP. Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. Journal of Immunology (Baltimore, Md. : 1950). 176: 5255-66. PMID 16621991 DOI: 10.4049/jimmunol.176.9.5255  0.391
2006 Overwijk WW, de Visser KE, Tirion FH, de Jong LA, Pols TW, van der Velden YU, van den Boorn JG, Keller AM, Buurman WA, Theoret MR, Blom B, Restifo NP, Kruisbeek AM, Kastelein RA, Haanen JB. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. Journal of Immunology (Baltimore, Md. : 1950). 176: 5213-22. PMID 16621986 DOI: 10.4049/Jimmunol.176.9.5213  0.696
2006 Hinrichs CS, Gattinoni L, Restifo NP. Programming CD8+ T cells for effective immunotherapy Current Opinion in Immunology. 18: 363-370. PMID 16616471 DOI: 10.1016/J.Coi.2006.03.009  0.483
2006 Rosenberg SA, Sherry RM, Morton KE, Yang JC, Topalian SL, Royal RE, Kammula US, Restifo NP, Hughes MS, Schwarz SL, Ngo LT, Mavroukakis SA, White DE. Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines. Journal of Immunotherapy (Hagerstown, Md. : 1997). 29: 224-31. PMID 16531823 DOI: 10.1097/01.Cji.0000190399.98802.10  0.353
2006 Schiavo R, Baatar D, Olkhanud P, Indig FE, Restifo N, Taub D, Biragyn A. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood. 107: 4597-605. PMID 16514063 DOI: 10.1182/Blood-2005-08-3207  0.455
2006 Hwang LN, Yu Z, Palmer DC, Restifo NP. The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor. Cancer Research. 66: 1132-8. PMID 16424050 DOI: 10.1158/0008-5472.Can-05-1679  0.578
2006 Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y, Zeng G, Wunderlich JR, Nguyen DM, Restifo NP, Schrump DS. De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Research. 66: 1105-13. PMID 16424047 DOI: 10.1158/0008-5472.Can-05-3020  0.49
2006 Zhao Y, Zheng Z, Cohen CJ, Gattinoni L, Palmer DC, Restifo NP, Rosenberg SA, Morgan RA. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Molecular Therapy : the Journal of the American Society of Gene Therapy. 13: 151-9. PMID 16140584 DOI: 10.1016/J.Ymthe.2005.07.688  0.48
2006 Boni A, Muranski P, Wrzesinski C, Kaiser A, Paulos C, Palmer D, Gattinoni L, Restifo NP. Partly MHC Matched Allogeneic Tumor Specific T Cells Mediate Tumor Regression without Inducing GVHD in Immunosuppressed Host. Blood. 108: 5210-5210. DOI: 10.1182/Blood.V108.11.5210.5210  0.548
2006 Muranski P, Boni A, Paulos CM, Irvine KR, Antony PA, Restifo NP. Treatment of Established B16 Murine Melanoma Tumors with Tyrp-1 Specific CD4+ Lymphocytes. Blood. 108: 3688-3688. DOI: 10.1182/Blood.V108.11.3688.3688  0.589
2006 Rosenberg SA, Restifo NP. Response to comment on "tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma" [2] Journal of Immunology. 176: 4511-4512.  0.44
2005 Wang LX, Li R, Yang G, Lim M, O'Hara A, Chu Y, Fox BA, Restifo NP, Urba WJ, Hu HM. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Research. 65: 10569-77. PMID 16288050 DOI: 10.1158/0008-5472.Can-05-2117  0.559
2005 Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, Schwartzentruber D, Berman DM, Schwarz SL, Ngo LT, Mavroukakis SA, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. Journal of Immunology (Baltimore, Md. : 1950). 175: 6169-76. PMID 16237114 DOI: 10.4049/Jimmunol.175.9.6169  0.554
2005 Hinrichs CS, Palmer DC, Rosenberg SA, Restifo NP. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 517-24. PMID 16224268 DOI: 10.1097/01.Cji.0000177999.95831.7B  0.486
2005 Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. The Journal of Experimental Medicine. 202: 907-12. PMID 16203864 DOI: 10.1084/Jem.20050732  0.574
2005 Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6043-53. PMID 16087944 DOI: 10.1200/Jco.2005.06.205  0.479
2005 Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, Waldmann TA, Restifo NP. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proceedings of the National Academy of Sciences of the United States of America. 102: 9571-6. PMID 15980149 DOI: 10.1073/Pnas.0503726102  0.577
2005 Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. The Journal of Clinical Investigation. 115: 1616-26. PMID 15931392 DOI: 10.1172/Jci24480  0.579
2005 Borbulevych OY, Baxter TK, Yu Z, Restifo NP, Baker BM. Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. Journal of Immunology (Baltimore, Md. : 1950). 174: 4812-20. PMID 15814707 DOI: 10.4049/Jimmunol.174.8.4812  0.334
2005 Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2346-57. PMID 15800326 DOI: 10.1200/Jco.2005.00.240  0.374
2005 Wrzesinski C, Restifo NP. Less is more: Lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy Current Opinion in Immunology. 17: 195-201. PMID 15766681 DOI: 10.1016/J.Coi.2005.02.002  0.512
2005 Charo J, Finkelstein SE, Grewal N, Restifo NP, Robbins PF, Rosenberg SA. Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Research. 65: 2001-8. PMID 15753400 DOI: 10.1158/0008-5472.Can-04-2006  0.562
2005 Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, Rosenberg SA, Restifo NP. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. Journal of Immunology (Baltimore, Md. : 1950). 174: 2591-601. PMID 15728465 DOI: 10.4049/Jimmunol.174.5.2591  0.715
2005 Antony PA, Restifo NP. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2 Journal of Immunotherapy. 28: 120-128. PMID 15725955 DOI: 10.1097/01.Cji.0000155049.26787.45  0.455
2005 Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends in Immunology. 26: 111-7. PMID 15668127 DOI: 10.1016/J.It.2004.12.003  0.585
2005 Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S. Immune selection of hot-spot β2-Microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy Journal of Immunology. 174: 1462-1471. PMID 15661905 DOI: 10.4049/Jimmunol.174.3.1462  0.452
2005 Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP, Berzofsky JA, Leonard WJ. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. The Journal of Experimental Medicine. 201: 139-48. PMID 15630141 DOI: 10.1084/Jem.20041057  0.379
2005 Restifo NP, Rosenberg SA. Use of standard criteria for assessment of cancer vaccines. The Lancet. Oncology. 6: 3-4. PMID 15629270 DOI: 10.1016/S1470-2045(04)01693-6  0.362
2005 Antony PA, Paulos C, Restifo N. IL-2 Paradoxically Controls Tolerance and Immunity to A Tumor/Self-Antigen Journal of Immunotherapy. 28: 647. DOI: 10.1097/01.Cji.0000191060.11630.7F  0.41
2005 Wrzesinski C, Gattinoni L, Palmer DC, Paulos CM, Yu Z, Rosenberg SA, Restifo NP. Hematopoietic Stem Cell Transplant With Lymphodepletion Augments T Cell-based Adoptive Immunotherapy Journal of Immunotherapy. 28: 619. DOI: 10.1097/01.Cji.0000190968.11149.79  0.396
2004 Palmer DC, Balasubramaniam S, Hanada K, Wrzesinski C, Yu Z, Farid S, Theoret MR, Hwang LN, Klebanoff CA, Gattinoni L, Goldstein AL, Yang JC, Restifo NP. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. Journal of Immunology (Baltimore, Md. : 1950). 173: 7209-16. PMID 15585842 DOI: 10.4049/Jimmunol.173.12.7209  0.562
2004 Lou Y, Wang G, Lizée G, Kim GJ, Finkelstein SE, Feng C, Restifo NP, Hwu P. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Research. 64: 6783-90. PMID 15374997 DOI: 10.1158/0008-5472.Can-04-1621  0.564
2004 Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nature Medicine. 10: 909-15. PMID 15340416 DOI: 10.1038/Nm1100  0.372
2004 Yu Z, Theoret MR, Touloukian CE, Surman DR, Garman SC, Feigenbaum L, Baxter TK, Baker BM, Restifo NP. Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. The Journal of Clinical Investigation. 114: 551-9. PMID 15314692 DOI: 10.1172/Jci21695  0.505
2004 Finkelstein SE, Heimann DM, Klebanoff CA, Antony PA, Gattinoni L, Hinrichs CS, Hwang LN, Palmer DC, Spiess PJ, Surman DR, Wrzesiniski C, Yu Z, Rosenberg SA, Restifo NP. Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. Journal of Leukocyte Biology. 76: 333-7. PMID 15155774 DOI: 10.1189/Jlb.0304120  0.55
2004 Leitner WW, Hwang LN, Bergmann-Leitner ES, Finkelstein SE, Frank S, Restifo NP. Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines Vaccine. 22: 1537-1544. PMID 15063579 DOI: 10.1016/J.Vaccine.2003.10.013  0.388
2004 Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, Tagaya Y, Rosenberg SA, Waldmann TA, Restifo NP. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proceedings of the National Academy of Sciences of the United States of America. 101: 1969-74. PMID 14762166 DOI: 10.1073/Pnas.0307298101  0.484
2004 Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Surman DR, Restifo NP. Acquisition of Terminal Effector Functions In Vitro Impairs In Vivo Anti-Tumor Efficacy Journal of Immunotherapy. 27: S2. DOI: 10.1097/00002371-200411000-00012  0.376
2004 Rosenberg SA, Yang JC, Restifo NP. Reply to "Cancer vaccines: pessimism in check" Nature Medicine. 10: 1279-1280. DOI: 10.1038/Nm1204-1279B  0.306
2004 Finkelstein S, Klebanoff C, Antony P, Gattinoni L, Heimann D, Hinrichs C, Hwang L, Palmer D, Spiess P, Rosenberg S, Restifo N. IFN-gamma production by adoptively transferred CD8+ T lymphocytes and host cells contributes to successful tumor immunotherapy Journal of the American College of Surgeons. 199: 90-91. DOI: 10.1016/J.Jamcollsurg.2004.05.197  0.5
2003 Murakami T, Cardones AR, Finkelstein SE, Restifo NP, Klaunberg BA, Nestle FO, Castillo SS, Dennis PA, Hwang ST. Immune evasion by murine melanoma mediated through CC chemokine receptor-10. The Journal of Experimental Medicine. 198: 1337-47. PMID 14581607 DOI: 10.1084/Jem.20030593  0.509
2003 Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, Schwartzentruber DJ, Topalian SL, Restifo NP, Filie A, Chang R, Dudley ME. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 26: 385-93. PMID 12973027 DOI: 10.1097/00002371-200309000-00001  0.493
2003 Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, Theoret MR, Wunderlich JR, Hughes MS, Restifo NP, Rosenberg SA. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. Journal of Immunology (Baltimore, Md. : 1950). 171: 3287-95. PMID 12960359 DOI: 10.4049/Jimmunol.171.6.3287  0.463
2003 Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, ... ... Restifo NP, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. The Journal of Experimental Medicine. 198: 569-80. PMID 12925674 DOI: 10.1084/Jem.20030590  0.746
2003 Phan GQ, Touloukian CE, Yang JC, Restifo NP, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. Journal of Immunotherapy (Hagerstown, Md. : 1997). 26: 349-56. PMID 12843797 DOI: 10.1097/00002371-200307000-00007  0.46
2003 Leitner WW, Restifo NP. DNA vaccines and apoptosis: To kill or not to kill? Journal of Clinical Investigation. 112: 22-24. PMID 12840054 DOI: 10.1172/Jci19069  0.316
2003 Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America. 100: 8372-7. PMID 12826605 DOI: 10.1073/Pnas.1533209100  0.512
2003 Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Human Gene Therapy. 14: 709-14. PMID 12804135 DOI: 10.1089/104303403765255110  0.42
2003 Touloukian CE, Leitner WW, Schnur RE, Robbins PF, Li Y, Southwood S, Sette A, Rosenberg SA, Restifo NP. Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1. Journal of Immunology (Baltimore, Md. : 1950). 170: 1579-85. PMID 12538723 DOI: 10.4049/Jimmunol.170.3.1579  0.506
2003 Leitner WW, Hwang LN, deVeer MJ, Zhou A, Silverman RH, Williams BR, Dubensky TW, Ying H, Restifo NP. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nature Medicine. 9: 33-9. PMID 12496961 DOI: 10.1038/Nm813  0.39
2002 Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes Nature Immunology. 3: 999-1005. PMID 12407407 DOI: 10.1038/Ni1102-999  0.448
2002 Neeley YC, McDonagh KT, Overwijk WW, Restifo NP, Sanda MG. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC. The Prostate. 53: 183-91. PMID 12386918 DOI: 10.1002/Pros.10136  0.681
2002 Sloan JM, Kershaw MH, Touloukian CE, Lapointe R, Robbins PF, Restifo NP, Hwu P. MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells. Cancer Gene Therapy. 9: 946-50. PMID 12386833 DOI: 10.1038/Sj.Cgt.7700509  0.499
2002 Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (New York, N.Y.). 298: 850-4. PMID 12242449 DOI: 10.1126/Science.1076514  0.491
2002 Touloukian CE, Leitner WW, Robbins PF, Li YF, Kang X, Lapointe R, Hwu P, Rosenberg SA, Restifo NP. Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Cancer Research. 62: 5144-7. PMID 12234976  0.485
2002 Yu Z, Restifo NP. Cancer vaccines: Progress reveals new complexities Journal of Clinical Investigation. 110: 289-294. PMID 12163445 DOI: 10.1172/Jci16216  0.436
2002 Wang HY, Fu T, Wang G, Zeng G, Perry-Lalley DM, Yang JC, Restifo NP, Hwu P, Wang RF. Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. The Journal of Clinical Investigation. 109: 1463-70. PMID 12045260 DOI: 10.1172/Jci200215399  0.551
2002 Antony PA, Restifo NP. Do CD4+CD25+ immunoregulatory T cells hinder tumor immunotherapy? Journal of Immunotherapy. 25: 202-206. PMID 12000861 DOI: 10.1097/00002371-200205000-00002  0.551
2002 Restifo NP, Antony PA, Finkelstein SE, Leitner WW, Surman DP, Theoret MR, Touloukian CE. Assumptions of the tumor 'escape' hypothesis. Seminars in Cancer Biology. 12: 81-6. PMID 11926416 DOI: 10.1006/Scbi.2001.0399  0.467
2002 Perez-Diez A, Spiess PJ, Restifo NP, Matzinger P, Marincola FM. Intensity of the vaccine-elicited immune response determines tumor clearance Journal of Immunology. 168: 338-347. PMID 11751979 DOI: 10.4049/Jimmunol.168.1.338  0.452
2001 Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Current Protocols in Immunology / Edited by John E. Coligan ... [Et Al.]. Unit 20.1. PMID 18432774 DOI: 10.1002/0471142735.Im2001S39  0.647
2001 Touloukian CE, Leitner WW, Robbins PF, Rosenberg SA, Restifo NP. Mining the melanosome for tumor vaccine targets: P. polypeptide is a novel tumor-associated antigen Cancer Research. 61: 8100-8104. PMID 11719435  0.375
2001 Kershaw MH, Hsu C, Mondesire W, Parker LL, Wang G, Overwijk WW, Lapointe R, Yang JC, Wang RF, Restifo NP, Hwu P. Immunization against endogenous retroviral tumor-associated antigens. Cancer Research. 61: 7920-4. PMID 11691813  0.68
2001 van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. The Journal of Experimental Medicine. 194: 481-9. PMID 11514604 DOI: 10.1084/Jem.194.4.481  0.752
2001 Restifo NP. Hierarchy, tolerance, and dominance in the antitumor T-cell response Journal of Immunotherapy. 24: 193-194. PMID 11394495 DOI: 10.1097/00002371-200105000-00001  0.539
2001 Overwijk WW, Restifo NP. Creating therapeutic cancer vaccines: notes from the battlefield. Trends in Immunology. 22: 5-7. PMID 11286676 DOI: 10.1016/S1471-4906(00)01793-2  0.69
2001 Restifo NP. Countering the 'counterattack' hypothesis Nature Medicine. 7: 259. PMID 11231598 DOI: 10.1038/85357  0.433
2000 Overwijk WW, Restifo NP. Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Critical Reviews in Immunology. 20: 433-50. PMID 11396680 DOI: 10.1615/Critrevimmunol.V20.I6.10  0.716
2000 Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, Restifo NP, Zanovello P. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood. 96: 3838-46. PMID 11090068 DOI: 10.1182/Blood.V96.12.3838  0.48
2000 Restifo NP. Building better vaccines: How apoptotic cell death can induce inflammation and activate innate and adaptive immunity Current Opinion in Immunology. 12: 597-603. PMID 11007365 DOI: 10.1016/S0952-7915(00)00148-5  0.349
2000 Lee K, Overwijk WW, O'Toole M, Swiniarski H, Restifo NP, Dorner AJ, Wolf SF, Sturmhoefel K. Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 20: 589-96. PMID 10888115 DOI: 10.1089/10799900050044787  0.695
2000 Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. Journal of Immunology (Baltimore, Md. : 1950). 165: 1153-9. PMID 10878395 DOI: 10.4049/Jimmunol.165.2.1153  0.546
2000 Charles LG, Xie YC, Restifo NP, Roessler B, Sanda MG. Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development. World Journal of Urology. 18: 136-42. PMID 10854149 DOI: 10.1007/S003450050186  0.447
2000 Restifo NP. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape Nature Medicine. 6: 493-495. PMID 10802692 DOI: 10.1038/74955  0.411
2000 Xiang R, Lode HN, Chao TH, Ruehlmann JM, Dolman CS, Rodriguez F, Whitton JL, Overwijk WW, Restifo NP, Reisfeld RA. An autologous oral DNA vaccine protects against murine melanoma. Proceedings of the National Academy of Sciences of the United States of America. 97: 5492-7. PMID 10779556 DOI: 10.1073/Pnas.090097697  0.703
2000 Colella TA, Bullock TN, Russell LB, Mullins DW, Overwijk WW, Luckey CJ, Pierce RA, Restifo NP, Engelhard VH. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. The Journal of Experimental Medicine. 191: 1221-32. PMID 10748239 DOI: 10.1084/Jem.191.7.1221  0.663
2000 Touloukian CE, Leitner WW, Topalian SL, Li YF, Robbins PF, Rosenberg SA, Restifo NP. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice Journal of Immunology. 164: 3535-3542. PMID 10725708 DOI: 10.4049/Jimmunol.164.7.3535  0.504
2000 Overwijk WW, Theoret MR, Restifo NP. The future of interleukin-2: enhancing therapeutic anticancer vaccines. The Cancer Journal From Scientific American. 6: S76-80. PMID 10685664  0.67
2000 Bronte V, Apolloni E, Ronca R, Zamboni P, Overwijk WW, Surman DR, Restifo NP, Zanovello P. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Research. 60: 253-8. PMID 10667570  0.65
2000 Leitner WW, Ying H, Driver DA, Dubensky TW, Restifo NP. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors Cancer Research. 60: 51-55. PMID 10646851  0.316
2000 Surman DR, Dudley ME, Overwijk WW, Restifo NP. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. Journal of Immunology (Baltimore, Md. : 1950). 164: 562-5. PMID 10623795 DOI: 10.4049/Jimmunol.164.2.562  0.728
1999 Leitner WW, Ying H, Restifo NP. DNA and RNA-based vaccines: Principles, progress and prospects Vaccine. 18: 765-777. PMID 10580187 DOI: 10.1016/S0264-410X(99)00271-6  0.369
1999 Kaufman HL, Rao JB, Irvine KR, Bronte V, Rosenberg SA, Restifo NP, Irivine KR. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. Journal of Immunotherapy (Hagerstown, Md. : 1997). 22: 489-96. PMID 10570747 DOI: 10.1097/00002371-199911000-00003  0.41
1999 Terenzi F, DeVeer MJ, Ying H, Restifo NP, Williams BRG, Silverman RH. The antiviral enzymes PKR and RNase L suppress gene expression from viral and non-viral based vectors Nucleic Acids Research. 27: 4369-4375. PMID 10536144 DOI: 10.1093/Nar/27.22.4369  0.311
1999 Ying H, Zaks TZ, Wang RF, Irvine KR, Kammula US, Marincola FM, Leitner WW, Restifo NP. Cancer therapy using a self-replicating RNA vaccine. Nature Medicine. 5: 823-7. PMID 10395329 DOI: 10.1038/10548  0.435
1999 Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, Restifo NP. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation Journal of Immunology. 162: 5728-5737. PMID 10229805  0.462
1999 Zaks TZ, Chappell DB, Rosenberg SA, Restifo NP. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: Selective rescue by caspase inhibition Journal of Immunology. 162: 3273-3279. PMID 10092779  0.47
1999 Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 96: 2982-7. PMID 10077623 DOI: 10.1073/Pnas.96.6.2982  0.719
1999 Cormier JN, Panelli MC, Hackett JA, Bettinotti MP, Mixon A, Wunderlich J, Parker LL, Restifo NP, Ferrone S, Marincola FM. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. International Journal of Cancer. Journal International Du Cancer. 80: 781-90. PMID 10048982 DOI: 10.1002/(Sici)1097-0215(19990301)80:5<781::Aid-Ijc24>3.0.Co;2-A  0.419
1999 Xie YC, Hwang C, Overwijk W, Zeng Z, Eng MH, Mulé JJ, Imperiale MJ, Restifo NP, Sanda MG. Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen Journal of the National Cancer Institute. 91: 169-175. PMID 9923859 DOI: 10.1093/Jnci/91.2.169  0.723
1999 Restifo NP, Rosenberg SA. Developing recombinant and synthetic vaccines for the treatment of melanoma Current Opinion in Oncology. 11: 50-57. PMID 9914879 DOI: 10.1097/00001622-199901000-00012  0.426
1999 Chappell DB, Zaks TZ, Rosenberg SA, Restifo NP. Human melanoma cells do not express Fas (Apo-1/CD95) ligand Cancer Research. 59: 59-62. PMID 9892185  0.315
1999 Porgador A, Dorfman JR, Corral L, Strominger JL, Mandelboim O, Restifo NP. Tumor variability and sensitivity to T and NK cells: Implications for cancer immunotherapy Gann Monographs On Cancer Research. 48: 105-115.  0.399
1998 Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Seipp CA, Einhorn JH, Roberts B, White DE. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. Journal of the National Cancer Institute. 90: 1894-900. PMID 9862627 DOI: 10.1093/Jnci/90.24.1894  0.435
1998 Carroll MW, Overwijk WW, Surman DR, Tsung K, Moss B, Restifo NP. Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen. Journal of the National Cancer Institute. 90: 1881-7. PMID 9862625 DOI: 10.1093/Jnci/90.24.1881  0.683
1998 Bronte V, Wang M, Overwijk WW, Surman DR, Pericle F, Rosenberg SA, Restifo NP. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. Journal of Immunology (Baltimore, Md. : 1950). 161: 5313-20. PMID 9820504  0.678
1998 Chappell DB, Restifo NP. T cell-tumor cell: A fatal interaction? Cancer Immunology Immunotherapy. 47: 65-71. PMID 9769114 DOI: 10.1007/S002620050505  0.532
1998 Restifo NP. Cancer vaccines '98: A reductionistic approach Molecular Medicine Today. 4: 327. PMID 9755448 DOI: 10.1016/S1357-4310(98)01304-5  0.405
1998 Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization Journal of Experimental Medicine. 188: 1075-1082. PMID 9743526 DOI: 10.1084/Jem.188.6.1075  0.469
1998 Restifo NP, Surman DR, Zheng H, Palese P, Rosenberg SA, García-Sastre A. Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer Virology. 249: 89-97. PMID 9740780 DOI: 10.1006/Viro.1998.9330  0.307
1998 Surman DR, Irvine KR, Shulman EP, Allweis TM, Rosenberg SA, Restifo NP. Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization Journal of Immunological Methods. 214: 51-62. PMID 9692858 DOI: 10.1016/S0022-1759(98)00036-2  0.443
1998 Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. The Journal of Experimental Medicine. 188: 277-86. PMID 9670040 DOI: 10.1084/Jem.188.2.277  0.728
1998 Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine. 4: 321-7. PMID 9500606 DOI: 10.1038/Nm0398-321  0.376
1997 Porgador A, Mandelboim O, Restifo NP, Strominger JL. Natural killer cell lines kill autologous β2-microglobulin-deficient melanoma cells: Implications for cancer immunotherapy Proceedings of the National Academy of Sciences of the United States of America. 94: 13140-13145. PMID 9371813 DOI: 10.1073/Pnas.94.24.13140  0.54
1997 Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors Journal of the National Cancer Institute. 89: 1595-1601. PMID 9362157 DOI: 10.1093/Jnci/89.21.1595  0.462
1997 Kim CJ, Prevette T, Cormier J, Overwijk W, Roden M, Restifo NP, Rosenberg SA, Marincola FM. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro Journal of Immunotherapy. 20: 276-286. PMID 9220317 DOI: 10.1097/00002371-199707000-00004  0.734
1997 Overwijk WW, Surman DR, Tsung K, Restifo NP. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods (San Diego, Calif.). 12: 117-23. PMID 9184376 DOI: 10.1006/Meth.1997.0461  0.652
1997 Carroll MW, Overwijk WW, Chamberlain RS, Rosenberg SA, Moss B, Restifo NP. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine. 15: 387-94. PMID 9141209 DOI: 10.1016/S0264-410X(96)00195-8  0.639
1997 Zhai Y, Yang JC, Spiess P, Nishimura MI, Overwijk WW, Roberts B, Restifo NP, Rosenberg SA. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. Journal of Immunotherapy (Hagerstown, Md. : 1997). 20: 15-25. PMID 9101410 DOI: 10.1097/00002371-199701000-00002  0.704
1997 Bronte V, Carroll MW, Goletz TJ, Wang M, Overwijk WW, Marincola F, Rosenberg SA, Moss B, Restifo NP. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proceedings of the National Academy of Sciences of the United States of America. 94: 3183-8. PMID 9096367 DOI: 10.1073/Pnas.94.7.3183  0.668
1997 Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A Cancer Journal From Scientific American. 3: 37-44. PMID 9072306  0.35
1997 Irvine KR, Chamberlain RS, Shulman EP, Rosenberg SA, Restifo NP. Route of immunization and the therapeutic impact of recombinant anticancer vaccines Journal of the National Cancer Institute. 89: 390-392. PMID 9060962 DOI: 10.1093/Jnci/89.5.390  0.398
1997 Moss B, Carroll MW, Wyatt LS, Bennink JR, Hirsch VM, Goldstein S, Elkins WR, Fuerst TR, Lifson JD, Piatak M, Restifo NP, Overwijk W, Chamberlain R, Rosenberg SA, Sutter G. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Advances in Experimental Medicine and Biology. 397: 7-13. PMID 8718576 DOI: 10.1007/978-1-4899-1382-1_2  0.656
1997 Bronte V, Pericle F, Wang M, Overwijk WW, Restifo NP. Identification of a feed-back circuit regulating the immune response and operating under different conditions of immunosuppression Immunology Letters. 56: 247. DOI: 10.1016/S0165-2478(97)85983-4  0.565
1996 Restifo NP. The new vaccines: Building viruses that elicit antitumor immunity Current Opinion in Immunology. 8: 658-663. PMID 8902391 DOI: 10.1016/S0952-7915(96)80082-3  0.473
1996 Chamberlain RS, Carroll MW, Bronte V, Hwu P, Warren S, Yang JC, Nishimura M, Moss B, Rosenberg SA, Restifo NP. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Research. 56: 2832-6. PMID 8665522  0.366
1996 Rao JB, Chamberlain RS, Bronte V, Carroll MW, Irvine KR, Moss B, Rosenberg SA, Restifo NP. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. Journal of Immunology (Baltimore, Md. : 1950). 156: 3357-65. PMID 8617961  0.382
1996 Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. Journal of Immunology (Baltimore, Md. : 1950). 156: 224-31. PMID 8598466  0.307
1996 Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. Journal of the National Cancer Institute. 88: 100-8. PMID 8537970 DOI: 10.1093/Jnci/88.2.100  0.472
1996 Irvine KR, Chamberlain RS, Bronte V, Rosenberg SA, Restifo NP. UK route of administration of recombinant vaccinia vitas (rVV) vaccines effects the active treatment of cancer Faseb Journal. 10.  0.317
1995 Irvine KR, Restifo NP. The next wave of recombinant and synthetic anticancer vaccines Seminars in Cancer Biology. 6: 337-347. PMID 8938272 DOI: 10.1016/1044-579X(95)90003-9  0.46
1995 Wang M, Chen PW, Bronte V, Rosenberg SA, Restifo NP. Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 18: 139-46. PMID 8770769 DOI: 10.1097/00002371-199510000-00001  0.461
1995 Marincola FM, Shamamian P, Rivoltini L, Salgaller M, Cormier J, Restifo NP, Simonis TB, Venzon D, White DE, Parkinson DR. HLA Associations in the Antitumor Response Against Malignant Melanoma Journal of Immunotherapy. 18: 242-252. PMID 8680652 DOI: 10.1097/00002371-199511000-00005  0.315
1995 Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, Restifo NP. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. Journal of Immunology (Baltimore, Md. : 1950). 154: 5282-92. PMID 7730632  0.349
1995 Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA, Restifo NP. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. Journal of Immunology (Baltimore, Md. : 1950). 154: 4685-92. PMID 7722321  0.371
1995 Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, Simons JW. Molecular characterization of defective antigen processing in human prostate cancer. Journal of the National Cancer Institute. 87: 280-5. PMID 7707419 DOI: 10.1093/Jnci/87.4.280  0.436
1995 Jakobsen MK, Restifo NP, Cohen PA, Marincola FM, Bryan Cheshire L, Marston Linehan W, Rosenberg SA, Alexander RB. Defective major histocompatibility complex class i expression in a sarcomatoid renal cell carcinoma cell line Journal of Immunotherapy. 17: 222-228. PMID 7582258 DOI: 10.1097/00002371-199505000-00004  0.402
1995 McCabe BJ, Irvine KR, Nishimura MI, Yang JC, Spiess PJ, Shulman EP, Rosenberg SA, Restifo NP. Minimal Determinant Expressed by a Recombinant Vaccinia Virus Elicits Therapeutic Antitumor Cytolytic T Lymphocyte Responses Cancer Research. 55: 1741-1747. PMID 7536130  0.419
1994 Marincola FM, Ettinghausen S, Cohen PA, Cheshire LB, Restifo NP, Mulé JJ, Rosenberg SA. Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha Journal of Immunology. 152: 3500-3513. PMID 8144931  0.335
1994 Marincola FM, Shamamian P, Simonis TB, Abati A, Hackett J, O'Dea T, Fetsch P, Yannelli J, Restifo NP, Mulé JJ. Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 16: 13-23. PMID 8081556 DOI: 10.1097/00002371-199407000-00002  0.37
1994 Restifo NP, Minev BR, Taggarse AS, McFarland BJ, Wang M, Irvine KR. Enhancing the recognition of tumour associated antigens Folia Biologica. 40: 74-88. PMID 7958066  0.386
1994 Shamamian P, Mancini M, Kawakami Y, Restifo NP, Rosenberg SA, Topalian SL. Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest Cancer Immunology Immunotherapy. 39: 73-83. PMID 7519127 DOI: 10.1007/Bf01525312  0.542
1994 Lawson CM, Bennink JR, Restifo NP, Yewdell JW, Murphy BR. Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge Journal of Virology. 68: 3505-3511. PMID 7514677 DOI: 10.1128/Jvi.68.6.3505-3511.1994  0.319
1994 Marincola FM, Ettinghausen S, Cohen PA, Cheshire LB, Restifo NP, Mule JJ, Rosenberg SA. Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-α Journal of Immunology. 152: 3501-3513.  0.34
1993 Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mulé JJ, Rosenberg SA, Bennink JR. Identification of human cancers deficient in antigen processing Journal of Experimental Medicine. 177: 265-272. PMID 8426105 DOI: 10.1084/Jem.177.2.265  0.481
1993 Karp SE, Farber A, Salo JC, Hwu P, Jaffe G, Asher AL, Shiloni E, Restifo NP, Mule JJ, Rosenberg SA. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma: Tumor inhibition by IL-2 but not tumor necrosis factor Journal of Immunology. 150: 896-908. PMID 8423345  0.383
1993 Shiloni E, Karp SE, Custer MC, Shilyansky J, Restifo NP, Rosenberg SA, Mulé JJ. Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor. Cancer Immunology, Immunotherapy : Cii. 37: 286-92. PMID 8402732 DOI: 10.1007/Bf01518450  0.496
1993 Restifo NP, Kawakami Y, Marincola F, Shamamian P, Taggarse A, Esquivel F, Rosenberg SA. Molecular mechanisms used by tumors to escape immune recognition: Immunogenetherapy and the cell biology of major histocompatibility complex class I Journal of Immunotherapy. 14: 182-190. PMID 8297900 DOI: 10.1097/00002371-199310000-00004  0.499
1993 Kawakami Y, Nishimura MI, Restifo NP, Topalian SL, O'Neil BH, Shilyansky J, Yannelli JR, Rosenberg SA. T-cell recognition of human melanoma antigens. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 14: 88-93. PMID 8280705 DOI: 10.1097/00002371-199308000-00002  0.445
1993 Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mulé JJ, Rosenberg SA, Bennink JR. IDENTIFICATION OF HUMAN CANCERS DEFECTIVE IN ANTIGEN PROCESSING Journal of Immunotherapy. 13: 70. DOI: 10.1097/00002371-199301000-00051  0.309
1993 Yewdell JW, Anderson R, Cox JH, Eisenlohr LC, Esquivel F, Lapham C, Restifo NP, Bennink JR. The multiple uses of viruses for studying antigen processing Seminars in Virology. 4: 109-116. DOI: 10.1006/Smvy.1993.1005  0.434
1992 Restifo NP, Spiess PJ, Karp SE, Mulé JJ, Rosenberg SA. A nonimmunogenic sarcoma transduced with the cDNA for interferon γ elicits CD8+ T cells against the wild-type tumor: Correlation with antigen presentation capability Journal of Experimental Medicine. 175: 1423-1431. PMID 1588273 DOI: 10.1084/Jem.175.6.1423  0.573
1992 Karp SE, Hwu P, Farber A, Restifo NP, Kriegler M, Mulé JJ, Rosenberg SA. In vivo activity of tumor necrosis factor (TNF) mutants: Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor Journal of Immunology. 149: 2076-2081. PMID 1517571  0.322
1992 Restifo NP, Spiess PJ, Mulé JJ, Rosenberg SA. GENE-MODIFICATION CORRECTS AN ANTIGEN PRESENTATION DEFECT IN A NON-IMMUNOGENIC SARCOMA AND ELICITS CD8+ T CELLS REACTIVE AGAINST THE WILD-TYPE TUMOR Journal of Immunotherapy. 11: 140. DOI: 10.1097/00002371-199202000-00050  0.513
1991 Asher AL, Mule JJ, Kasid A, Restifo NP, Salo JC, Reichert CM, Jaffe G, Fendly B, Kriegler M, Rosenberg SA. Murine tumor cells transduced with the gene for tumor necrosis factor-α: Evidence for paracrine immune effects of tumor necrosis factor against tumors Journal of Immunology. 146: 3227-3234. PMID 2016545  0.353
1991 Restifo NP, Esquivel F, Asher AL, Stötter H, Barth RJ, Bennink JR, Mulé JJ, Yewdell JW, Rosenberg SA. Defective presentation of endogenous antigens by a murine sarcoma: Implications for the failure of an anti-tumor immune response Journal of Immunology. 147: 1453-1459. PMID 1907999  0.319
Show low-probability matches.